Condensed Notes to Consolidated Financial Statements (Unaudited)
(in millions, except share and per share data)
|
|
1.
|
Background and Basis of Presentation
|
Hillenbrand, Inc. (the “Company” or “Hillenbrand”) is a global diversified industrial company with multiple leading brands that serve a wide variety of industries around the world. The Company strives to provide superior return for our shareholders, exceptional value for our customers, great professional opportunities for our employees, and to be responsible to our communities through deployment of the Hillenbrand Operating Model (“HOM”). The HOM is a consistent and repeatable framework designed to produce sustainable and predictable results. The HOM describes the Company’s mission, vision, values, and mindset as leaders; applies our management practices in Strategy Management, Segmentation, Lean, Talent Development, and Acquisitions; and prescribes three steps (Understand, Focus, and Grow) designed to make the Company’s businesses both bigger and better. The Company’s goal is to continue developing Hillenbrand as a world-class global diversified industrial company through the deployment of the HOM.
On July 12, 2019, Hillenbrand entered into a definitive agreement (the “Merger Agreement”) to acquire Milacron Holdings Corp. (“Milacron”) in a cash and stock merger transaction. The Company completed the acquisition on November 21, 2019 through a merger of its wholly-owned subsidiary with and into Milacron, resulting in ownership of 100% of Milacron’s common stock that was issued and outstanding after the merger. The Consolidated Financial Statements include the financial results of Milacron from the date of acquisition. See Note 4 for further information on the acquisition.
Hillenbrand’s portfolio is composed of three reportable business segments: the Process Equipment Group, Milacron®, and Batesville®. The Process Equipment Group businesses design, develop, manufacture, and service highly engineered industrial equipment around the world. Milacron is a global leader in highly engineered and customized systems in plastic technology and processing. Batesville is a recognized leader in the death care industry in North America. “Hillenbrand,” the “Company,” “we,” “us,” “our,” and similar words refer to Hillenbrand and its subsidiaries within this Form 10-Q unless context otherwise requires.
The accompanying unaudited Consolidated Financial Statements include the accounts of Hillenbrand and its subsidiaries. They also include two subsidiaries where the Company’s ownership percentage is less than 100%. The Company’s fiscal year ends on September 30. Unless otherwise stated, references to years relate to fiscal years.
These unaudited Consolidated Financial Statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements and therefore do not include all information required in accordance with United States generally accepted accounting principles (“GAAP”). The unaudited Consolidated Financial Statements have been prepared on the same basis as, and should be read in conjunction with, the audited Consolidated Financial Statements and notes thereto included in the Company’s latest Annual Report on Form 10-K for the year ended September 30, 2019, as filed with the SEC. In the opinion of management, these Consolidated Financial Statements reflect all adjustments necessary to present a fair statement of the Company’s consolidated financial position and the consolidated results of operations and cash flows as of the dates and for the periods presented. The interim period results are subject to variation and are not necessarily indicative of the results of operations to be expected for the full fiscal year.
The preparation of the Consolidated Financial Statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. Examples of such estimates include, but are not limited to, revenue recognition under the percentage-of-completion method, preliminary purchase price allocations, determination of reporting unit and identifiable intangible asset fair value, and the establishment of reserves related to customer rebates, doubtful accounts, warranties, early-pay discounts, inventories, income taxes, litigation, self-insurance, and progress toward achievement of performance criteria under incentive compensation programs.
On March 11, 2020, the World Health Organization declared the outbreak of the novel strain of coronavirus (“COVID-19”) a global pandemic and recommended containment and mitigation measures worldwide, and the effects of the COVID-19 pandemic and such associated measures on management’s estimates and results of operations through March 31, 2020 are reflected in the Consolidated Financial Statements. Events and changes in circumstances arising after March 31, 2020, including those resulting from the ongoing impacts of the COVID-19 pandemic, will be reflected in management’s estimates for future periods in subsequent periodic filings.
|
|
2.
|
Summary of Significant Accounting Policies
|
The significant accounting policies used in preparing the Consolidated Financial Statements are consistent with the accounting policies described in the Company’s Annual Report on Form 10-K for 2019, except as described below.
Recently Adopted Accounting Standards
In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (“ASU 2016-02”). ASU 2016-02 requires lessees to recognize a right of use asset and related lease liability for leases that have terms of more than twelve months. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or finance, with the classifications based on criteria that are similar to those applied under the current lease guidance, without the explicit bright lines. ASU 2016-02 became effective for the Company’s fiscal year that began on October 1, 2019. The Company adopted ASU 2016-02 under the allowable transition method to use the effective date as the date of initial application on transition without adjusting the comparative periods presented (modified retrospective method).
At transition, the Company elected the package of practical expedients to not reassess prior conclusions related to contracts containing leases, lease classification, and initial direct costs. Additionally, ASU 2016-02 also provides practical expedients for an entity’s ongoing accounting. The Company elected to not separate lease and non-lease components. Additionally, the Company will not recognize an asset for leases with a term of twelve months or less and will apply a portfolio approach in determining discount rates.
The Company surveyed its businesses, assessed its portfolio of leases, and compiled a central repository of all leases. Additionally, the Company identified and implemented appropriate changes to policies, procedures, and controls pertaining to existing and future lease arrangements to support recognition and disclosure requirements under ASU 2016-02. As a result of the adoption of ASU 2016-02, the Company recorded right-of-use assets of $165.0 and corresponding lease liabilities of $162.5 for its operating leases at March 31, 2020. The adoption of ASU 2016-02 did not have a material impact to the Consolidated Statements of Operations or Consolidated Statements of Cash Flows. See Note 6 for additional information.
In February 2018, the FASB issued ASU 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (“ASU 2018-02”). ASU 2018-02 allows for the reclassification of stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) from accumulated other comprehensive loss to retained earnings. The Company adopted ASU 2018-02 on October 1, 2019, which resulted in a decrease to accumulated other comprehensive loss and an increase to retained earnings of $6.0 each on the Consolidated Balance Sheets, primarily related to deferred taxes previously recorded for pension and other postretirement benefits. The adoption of ASU 2018-02 did not have an impact to the Consolidated Statements of Operations or Consolidated Statements of Cash Flows.
Recently Issued Accounting Standards
In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Statements (“ASU 2016-13”). ASU 2016-13 replaces the current incurred loss impairment model with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to determine credit loss estimates. ASU 2016-13 will be effective for the Company’s fiscal year beginning on October 1, 2020. The Company is currently evaluating the impact that ASU 2016-13 will have on the Consolidated Financial Statements.
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-13”). ASU 2019-13 clarifies and simplifies accounting for income taxes by eliminating certain exceptions for intraperiod tax allocation principles, the methodology for calculating income tax rates in an interim period, and recognition of deferred taxes for outside basis differences in an investment, among other updates. ASU 2019-12 will be effective for the Company’s fiscal year beginning on October 1, 2021. The Company is currently evaluating the impact of ASU 2019-12 on the Consolidated Financial Statements
No other new accounting pronouncements recently adopted or issued had or are expected to have a material impact on the Consolidated Financial Statements.
Net revenue includes gross revenue less sales discounts, customer rebates, sales incentives, and product returns, all of which require the Company to make estimates for the portion of these allowances that have yet to be credited or paid to customers. The Company estimates these allowances using the expected value method, which is based upon historical rates and projections of customer purchases toward contractual rebate thresholds.
Contract balances
The balance in receivables from long-term manufacturing contracts at March 31, 2020 and September 30, 2019 was $187.3 and $181.1, respectively. The change was driven by the impact of net revenue recognized prior to billings. The balance in the liabilities from long-term manufacturing contracts and advances at March 31, 2020 and September 30, 2019 was $176.6 and $158.2, respectively, and consists primarily of cash payments received in advance of satisfying performance obligations. The revenue recognized for the six months ended March 31, 2020 and 2019 related to liabilities from long-term manufacturing contracts and advances as of September 30, 2019 and 2018 was $87.8 and $107.0, respectively. During the three and six months ended March 31, 2020 and 2019, the adjustments related to performance obligations satisfied in previous periods were immaterial.
Transaction price allocated to the remaining performance obligations
As of March 31, 2020, the aggregate amount of transaction price of remaining performance obligations within the Process Equipment Group and Milacron reportable segments, which corresponds to backlog as defined in Item 2 of this Form 10-Q, was $1,169.5. Approximately 83% of these performance obligations are expected to be satisfied over the next twelve months, and the remaining performance obligations, primarily within one to three years.
Disaggregation of revenue
As a result of completing the acquisition of Milacron during the current fiscal year, the Company now sells products in the following additional end markets: custom molders, automotive, consumer goods, packaging, electronics, and construction. The following tables present net revenue by end market, which include reclassifications in the prior year period to conform to the current year presentation:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2020
|
|
Six Months Ended March 31, 2020
|
|
Process Equipment Group
|
|
Milacron
|
|
Batesville
|
|
Total
|
|
Process Equipment Group
|
|
Milacron
|
|
Batesville
|
|
Total
|
End Market
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plastics
|
$
|
206.6
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
206.6
|
|
|
$
|
408.7
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
408.7
|
|
Automotive
|
—
|
|
|
38.1
|
|
|
—
|
|
|
38.1
|
|
|
—
|
|
|
63.2
|
|
|
—
|
|
|
63.2
|
|
Chemicals
|
24.1
|
|
|
—
|
|
|
—
|
|
|
24.1
|
|
|
48.4
|
|
|
—
|
|
|
—
|
|
|
48.4
|
|
Consumer goods
|
—
|
|
|
19.3
|
|
|
—
|
|
|
19.3
|
|
|
—
|
|
|
37.6
|
|
|
—
|
|
|
37.6
|
|
Food and pharmaceuticals
|
17.2
|
|
|
—
|
|
|
—
|
|
|
17.2
|
|
|
35.2
|
|
|
—
|
|
|
—
|
|
|
35.2
|
|
Custom molders
|
—
|
|
|
21.3
|
|
|
—
|
|
|
21.3
|
|
|
—
|
|
|
38.1
|
|
|
—
|
|
|
38.1
|
|
Packaging
|
—
|
|
|
22.8
|
|
|
—
|
|
|
22.8
|
|
|
—
|
|
|
36.6
|
|
|
—
|
|
|
36.6
|
|
Construction
|
—
|
|
|
14.9
|
|
|
—
|
|
|
14.9
|
|
|
—
|
|
|
31.8
|
|
|
—
|
|
|
31.8
|
|
Minerals and mining
|
15.4
|
|
|
—
|
|
|
—
|
|
|
15.4
|
|
|
28.7
|
|
|
—
|
|
|
—
|
|
|
28.7
|
|
Electronics
|
—
|
|
|
14.5
|
|
|
—
|
|
|
14.5
|
|
|
—
|
|
|
22.8
|
|
|
—
|
|
|
22.8
|
|
Death care
|
—
|
|
|
—
|
|
|
138.8
|
|
|
138.8
|
|
|
—
|
|
|
—
|
|
|
265.8
|
|
|
265.8
|
|
Other industrial
|
47.8
|
|
|
68.1
|
|
|
—
|
|
|
115.9
|
|
|
96.7
|
|
|
102.2
|
|
|
—
|
|
|
198.9
|
|
Total
|
$
|
311.1
|
|
|
$
|
199.0
|
|
|
$
|
138.8
|
|
|
$
|
648.9
|
|
|
$
|
617.7
|
|
|
$
|
332.3
|
|
|
$
|
265.8
|
|
|
$
|
1,215.8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2019
|
|
Six Months Ended March 31, 2019
|
|
Process Equipment Group
|
|
Batesville
|
|
Total
|
|
Process Equipment Group
|
|
Batesville
|
|
Total
|
End Market
|
|
|
|
|
|
|
|
|
|
|
|
Plastics
|
$
|
202.2
|
|
|
$
|
—
|
|
|
$
|
202.2
|
|
|
$
|
363.1
|
|
|
$
|
—
|
|
|
$
|
363.1
|
|
Chemicals
|
22.9
|
|
|
—
|
|
|
22.9
|
|
|
52.5
|
|
|
—
|
|
|
52.5
|
|
Food and pharmaceuticals
|
24.4
|
|
|
—
|
|
|
24.4
|
|
|
40.9
|
|
|
—
|
|
|
40.9
|
|
Minerals and mining
|
22.2
|
|
|
—
|
|
|
22.2
|
|
|
50.2
|
|
|
—
|
|
|
50.2
|
|
Death care
|
—
|
|
|
137.9
|
|
|
137.9
|
|
|
—
|
|
|
266.0
|
|
|
266.0
|
|
Other industrial
|
55.0
|
|
|
—
|
|
|
55.0
|
|
|
102.2
|
|
|
—
|
|
|
102.2
|
|
Total
|
$
|
326.7
|
|
|
$
|
137.9
|
|
|
$
|
464.6
|
|
|
$
|
608.9
|
|
|
$
|
266.0
|
|
|
$
|
874.9
|
|
The following tables present net revenue by products and services:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2020
|
|
Six Months Ended March 31, 2020
|
|
Process Equipment Group
|
|
Milacron
|
|
Batesville
|
|
Total
|
|
Process Equipment Group
|
|
Milacron
|
|
Batesville
|
|
Total
|
Products and Services
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equipment
|
$
|
207.9
|
|
|
$
|
99.0
|
|
|
$
|
—
|
|
|
$
|
306.9
|
|
|
$
|
413.9
|
|
|
$
|
181.2
|
|
|
$
|
—
|
|
|
$
|
595.1
|
|
Parts and services
|
103.2
|
|
|
58.3
|
|
|
—
|
|
|
161.5
|
|
|
203.8
|
|
|
90.5
|
|
|
—
|
|
|
294.3
|
|
Death care
|
—
|
|
|
—
|
|
|
138.8
|
|
|
138.8
|
|
|
—
|
|
|
—
|
|
|
265.8
|
|
|
265.8
|
|
Other
|
—
|
|
|
41.7
|
|
|
—
|
|
|
41.7
|
|
|
—
|
|
|
60.6
|
|
|
—
|
|
|
60.6
|
|
Total
|
$
|
311.1
|
|
|
$
|
199.0
|
|
|
$
|
138.8
|
|
|
$
|
648.9
|
|
|
$
|
617.7
|
|
|
$
|
332.3
|
|
|
$
|
265.8
|
|
|
$
|
1,215.8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2019
|
|
Six Months Ended March 31, 2019
|
|
Process Equipment Group
|
|
Batesville
|
|
Total
|
|
Process Equipment Group
|
|
Batesville
|
|
Total
|
Products and Services
|
|
|
|
|
|
|
|
|
|
|
|
Equipment
|
$
|
227.6
|
|
|
$
|
—
|
|
|
$
|
227.6
|
|
|
$
|
411.0
|
|
|
$
|
—
|
|
|
$
|
411.0
|
|
Parts and services
|
99.1
|
|
|
—
|
|
|
99.1
|
|
|
197.9
|
|
|
—
|
|
|
197.9
|
|
Death care
|
—
|
|
|
137.9
|
|
|
137.9
|
|
|
—
|
|
|
266.0
|
|
|
266.0
|
|
Total
|
$
|
326.7
|
|
|
$
|
137.9
|
|
|
$
|
464.6
|
|
|
$
|
608.9
|
|
|
$
|
266.0
|
|
|
$
|
874.9
|
|
The following tables present net revenue by timing of transfer:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2020
|
|
Six Months Ended March 31, 2020
|
|
Process Equipment Group
|
|
Milacron
|
|
Batesville
|
|
Total
|
|
Process Equipment Group
|
|
Milacron
|
|
Batesville
|
|
Total
|
Timing of Transfer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Point in time
|
$
|
149.4
|
|
|
$
|
199.0
|
|
|
$
|
138.8
|
|
|
$
|
487.2
|
|
|
$
|
296.7
|
|
|
$
|
332.3
|
|
|
$
|
265.8
|
|
|
$
|
894.8
|
|
Over time
|
161.7
|
|
|
—
|
|
|
—
|
|
|
161.7
|
|
|
321.0
|
|
|
—
|
|
|
—
|
|
|
321.0
|
|
Total
|
$
|
311.1
|
|
|
$
|
199.0
|
|
|
$
|
138.8
|
|
|
$
|
648.9
|
|
|
$
|
617.7
|
|
|
$
|
332.3
|
|
|
$
|
265.8
|
|
|
$
|
1,215.8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2019
|
|
Six Months Ended March 31, 2019
|
|
Process Equipment Group
|
|
Batesville
|
|
Total
|
|
Process Equipment Group
|
|
Batesville
|
|
Total
|
Timing of Transfer
|
|
|
|
|
|
|
|
|
|
|
|
Point in time
|
$
|
176.8
|
|
|
$
|
137.9
|
|
|
$
|
314.7
|
|
|
$
|
340.5
|
|
|
$
|
266.0
|
|
|
$
|
606.5
|
|
Over time
|
149.9
|
|
|
—
|
|
|
149.9
|
|
|
268.4
|
|
|
—
|
|
|
268.4
|
|
Total
|
$
|
326.7
|
|
|
$
|
137.9
|
|
|
$
|
464.6
|
|
|
$
|
608.9
|
|
|
$
|
266.0
|
|
|
$
|
874.9
|
|
|
|
4.
|
Business Acquisitions and Divestitures
|
Acquisition of Milacron
Background
On November 21, 2019, the Company completed the acquisition of Milacron, a global leader in highly engineered and customized systems in plastic technology and processing, through a merger of its wholly-owned subsidiary with and into Milacron, resulting in ownership of 100% of Milacron common stock that was issued and outstanding after the acquisition. The acquisition provides Hillenbrand with increased scale and meaningful product diversification, enhancing its ability to serve customers with expanded capabilities across the plastics value chain.
The results of Milacron are reported separately in its own reportable segment. See Note 17 for further information.
Purchase price consideration
As a result of the acquisition, Milacron stockholders received $11.80 in cash per share and a fixed exchange ratio of 0.1612 shares of Hillenbrand common stock for each share of Milacron common stock they owned, with cash paid in lieu of fractional shares. In addition, concurrent with the closing of the acquisition, the Company made a cash payment of $772.9 to repay outstanding Milacron debt, including accrued interest. The Company funded the acquisition through a combination of cash on hand, new debt financing, and the issuance of common stock. See Note 8 for a discussion of the debt financing.
Pursuant to the Merger Agreement, certain of Milacron’s outstanding stock options, restricted stock awards, restricted stock unit awards, and performance stock unit awards immediately vested and converted into the right to receive $11.80 per share in cash and 0.1612 shares of Hillenbrand common stock per share. Additionally, certain of Milacron’s stock appreciation rights were canceled and converted into the right to receive a lump sum cash payment. The fair value of share-based equity awards was apportioned between purchase price consideration and immediate expense. The portion of the fair value of partially vested awards associated with pre-acquisition service of Milacron employees represented a component of the total purchase price consideration, while the remaining portion of the fair value was immediately recognized as expense within operating expenses in the Consolidated Statement of Operations during the six months ended March 31, 2020.
The following table summarizes the aggregate purchase price consideration to acquire Milacron:
|
|
|
|
|
Cash consideration paid to Milacron stockholders
|
$
|
835.9
|
|
Repayment of Milacron debt, including accrued interest
|
772.9
|
|
Cash consideration paid to settle outstanding share-based equity awards
|
34.2
|
|
Total cash consideration
|
1,643.0
|
|
Fair value of Hillenbrand common stock issued to Milacron stockholders (1)
|
356.9
|
|
Stock consideration issued to settle outstanding share-based equity awards (1)
|
14.4
|
|
Total consideration transferred
|
2,014.3
|
|
Portion of cash settlement of outstanding share-based equity awards recognized as expense (2)
|
(14.1
|
)
|
Portion of stock settlement of outstanding share-based equity awards recognized as expense (2)
|
(5.9
|
)
|
Total purchase price consideration
|
$
|
1,994.3
|
|
|
|
(1)
|
The fair value of the 11.4 million shares of Hillenbrand’s common stock issued as of the acquisition date was determined based on a per share price of $31.26, which was the closing price of Hillenbrand’s common stock on November 20, 2019, the last trading day before the acquisition closed on November 21, 2019. This includes a nominal amount of cash paid in lieu of fractional shares. Additionally, 0.5 million shares of Hillenbrand’s common stock were issued to settle certain of Milacron’s outstanding share-based equity awards, as previously discussed.
|
|
|
(2)
|
In total, $20.0 was immediately recognized as expense within operating expenses in the Consolidated Statement of Operations during the six months ended March 31, 2020, which represents the portion of the fair value of outstanding share-based equity awards that was not associated with pre-acquisition service of Milacron employees, as previously discussed.
|
Purchase price allocation
The acquisition was accounted for as a business combination in accordance with Accounting Standards Codification (“ASC”) Topic 805, Business Combinations. The purchase price was allocated to the assets acquired and liabilities assumed based on management’s estimate of the respective fair values at the date of acquisition. Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the estimated future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. The factors contributing to the recognition of goodwill were based on strategic benefits that are expected to be realized from the acquisition. None of the goodwill is expected to be deductible for income tax purposes.
The following table summarizes preliminary estimates of fair values of the assets acquired and liabilities assumed as of the acquisition date:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
November 21, 2019
(as initially reported)
|
|
Measurement Period Adjustments
|
|
November 21, 2019
(as adjusted)
|
Assets acquired:
|
|
|
|
|
|
Cash and cash equivalents
|
$
|
125.8
|
|
|
$
|
—
|
|
|
$
|
125.8
|
|
Trade receivables
|
135.5
|
|
|
1.3
|
|
|
136.8
|
|
Inventories
|
288.7
|
|
|
5.7
|
|
|
294.4
|
|
Prepaid expense and other current assets
|
64.3
|
|
|
1.3
|
|
|
65.6
|
|
Property, plant, and equipment
|
262.9
|
|
|
(17.7
|
)
|
|
245.2
|
|
Operating lease right-of-use assets
|
41.3
|
|
|
—
|
|
|
41.3
|
|
Identifiable intangible assets
|
865.0
|
|
|
(50.0
|
)
|
|
815.0
|
|
Goodwill
|
666.5
|
|
|
38.8
|
|
|
705.3
|
|
Other long-term assets
|
22.6
|
|
|
2.7
|
|
|
25.3
|
|
Total assets acquired
|
2,472.6
|
|
—
|
|
(17.9
|
)
|
|
2,454.7
|
|
|
|
|
|
|
|
Liabilities assumed:
|
|
|
|
|
|
Trade accounts payable
|
110.2
|
|
|
—
|
|
|
110.2
|
|
Liabilities from long-term manufacturing contracts and advances
|
32.7
|
|
|
—
|
|
|
32.7
|
|
Accrued compensation
|
23.2
|
|
|
(2.4
|
)
|
|
20.8
|
|
Other current liabilities
|
72.2
|
|
|
(0.3
|
)
|
|
71.9
|
|
Accrued pension and postretirement healthcare
|
29.4
|
|
|
—
|
|
|
29.4
|
|
Deferred income taxes
|
166.3
|
|
|
(15.2
|
)
|
|
151.1
|
|
Operating lease liabilities - long-term
|
31.2
|
|
|
—
|
|
|
31.2
|
|
Other long-term liabilities
|
13.1
|
|
|
—
|
|
|
13.1
|
|
Total liabilities assumed
|
478.3
|
|
—
|
|
(17.9
|
)
|
|
460.4
|
|
|
|
|
|
|
|
Total purchase price consideration
|
$
|
1,994.3
|
|
|
$
|
—
|
|
|
$
|
1,994.3
|
|
Measurement period adjustments
The preliminary purchase price allocation was based upon a preliminary valuation, and the Company’s estimates and assumptions are subject to change within the measurement period (defined as one year following the acquisition date). As a result of further refining its estimates and assumptions during the current quarter, the Company recorded measurement period adjustments to the initial opening balance sheet as shown in the table above. Adjustments were primarily made to property, plant, and equipment, identifiable intangible assets, goodwill, and deferred income taxes. Due to the timing of the acquisition, which was completed in the middle of the Company’s previous quarter, there were no measurement period adjustments materially impacting earnings that would have been recorded in the previous reporting period if the adjustments had been recognized as of the acquisition date.
As of March 31, 2020, the allocation of the purchase price has not been finalized and the one-year measurement period has not ended. The primary areas of the preliminary purchase price allocation that are not yet finalized relate to the fair value of certain tangible assets acquired and liabilities assumed, the valuation of identifiable intangible assets acquired and deferred income taxes. The Company expects to continue to obtain information for the purpose of determining the fair value of the assets acquired and liabilities assumed at the acquisition date throughout the remainder of the measurement period.
Intangible assets identified
The preliminary purchase price allocation included $815.0 of acquired identifiable intangible assets. The preliminary fair value of the identifiable intangible assets has been estimated using the income approach through a discounted cash flow analysis. The cash flows are based on estimates used to price the Milacron acquisition, and the discount rates applied were benchmarked with reference to the implied rate of return to the Company’s pricing model and the weighted-average cost of capital. Definite-lived intangible assets are being amortized over the estimated useful life on a straight-line basis. The determination of the useful lives is based upon various industry studies, historical acquisition experience, economic factors, and future cash flows of the Company post-acquisition of Milacron. In addition, Hillenbrand reviewed certain technological trends and considered the relative stability in the current Milacron customer base.
The preliminary amounts allocated to intangible assets are as follows:
|
|
|
|
|
|
|
|
|
|
Gross Carrying Amount
|
|
Weighted-Average Useful Life
|
Customer relationships
|
|
$
|
560.0
|
|
|
19 years
|
Trade names
|
|
150.0
|
|
|
Indefinite
|
Technology, including patents
|
|
95.0
|
|
|
10 years
|
Backlog
|
|
10.0
|
|
|
3 months
|
Total
|
|
$
|
815.0
|
|
|
|
The Company is required to provide additional disclosures about fair value measurements as part of the Consolidated Financial Statements for each major category of assets and liabilities measured at fair value on a nonrecurring basis (including business acquisitions). The working capital assets and liabilities, as well as the property, plant, and equipment acquired, were valued using Level 2 inputs which included data points that are observable, such as definitive sales agreements, appraisals or established market values of comparable assets (market approach). Goodwill and identifiable intangible assets were valued using Level 3 inputs, which are unobservable by nature, and included internal estimates of future cash flows (income approach). Significant increases (decreases) in any of those unobservable inputs in isolation would result in a significantly higher (lower) fair value measurement. Management used a third-party valuation firm to assist in the determination of the preliminary purchase accounting fair values, and specifically those considered Level 3 measurements along with Level 2 measurements for certain tangible assets. Management ultimately oversees the third-party valuation firm to ensure that the transaction-specific assumptions are appropriate for the Company.
Impact on results of operations
The results of Milacron’s operations have been included in Hillenbrand’s Consolidated Financial Statements since the November 21, 2019 acquisition date. The following table provides the results of operations for Milacron included in Hillenbrand’s Consolidated Statements of Operations for the three and six months ended March 31, 2020:
|
|
|
|
|
|
|
|
|
|
Three Months Ended
March 31, 2020
|
|
Six Months Ended
March 31, 2020
|
Net revenue
|
$
|
199.0
|
|
|
$
|
332.3
|
|
Loss before income taxes
|
(30.2
|
)
|
|
(29.5
|
)
|
In connection with the acquisition of Milacron, the Company incurred a total of $3.9 and $57.7 of business acquisition and integration costs during the three and six months ended March 31, 2020, respectively, which were recorded within operating expenses in the Consolidated Statements of Operations.
Supplemental Pro Forma Information
The supplemental pro forma financial information presented below is for illustrative purposes only and is not necessarily indicative of the financial position or results of operations that would have been realized if the Milacron acquisition had been completed on the date indicated, does not reflect synergies that might have been achieved, nor is it indicative of future operating results or financial position. The pro forma adjustments are based upon currently available information and certain assumptions that Hillenbrand believes are reasonable under the circumstances.
The supplemental pro forma financial information reflects pro forma adjustments to present the combined pro forma results of operations as if the Milacron acquisition had occurred on October 1, 2018 to give effect to certain events that Hillenbrand believes to be directly attributable to the Milacron acquisition. These pro forma adjustments primarily include:
|
|
•
|
an increase to depreciation and amortization expense that would have been recognized due to acquired tangible and identifiable intangible assets;
|
|
|
•
|
an adjustment to interest expense to reflect the additional borrowings of Hillenbrand and the repayment of Milacron’s historical debt in conjunction with the acquisition;
|
|
|
•
|
an adjustment to remove business acquisition and integration costs, inventory step-up costs, and backlog amortization during the three and six months ended March 31, 2020, as these costs are non-recurring in nature and will not have a continuing effect on Hillenbrand’s results; and
|
|
|
•
|
the related income tax effects of the adjustments noted above.
|
The supplemental pro forma financial information for the periods presented is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
March 31,
|
|
Six Months Ended
March 31,
|
|
2020
|
|
2019
|
|
2020
|
|
2019
|
Net revenue
|
$
|
648.9
|
|
|
$
|
713.3
|
|
|
$
|
1,331.5
|
|
|
$
|
1,413.1
|
|
Net (loss) income attributable to Hillenbrand
|
(46.8
|
)
|
|
37.5
|
|
|
(31.3
|
)
|
|
67.4
|
|
|
|
|
|
|
|
|
|
Net income attributable to Hillenbrand — per share of common stock:
|
|
|
|
|
|
|
|
Basic (loss) earnings per share
|
$
|
(0.62
|
)
|
|
$
|
0.50
|
|
|
$
|
(0.42
|
)
|
|
$
|
0.90
|
|
Diluted (loss) earnings per share
|
$
|
(0.62
|
)
|
|
$
|
0.50
|
|
|
$
|
(0.42
|
)
|
|
$
|
0.90
|
|
Sale of Milacron facility
In December 2019, the Company completed the sale of a Milacron manufacturing facility located in Germany. As a result of the sale, the Company received net cash proceeds of $13.1 during the six months ended March 31, 2020. There was no material impact to the Consolidated Statement of Operations resulting from the sale of the facility during the six months ended March 31, 2020.
Divestiture of Cimcool
On March 30, 2020, the Company completed the sale of its Cimcool business (“Cimcool”), which represented the former Fluids Technologies reportable segment of Milacron before its acquisition by the Company, to DuBois Chemicals, Inc. The sale resulted in cash proceeds received at closing of $222.4, net of cash divested.
In addition, the Company may receive contingent consideration for the sale of Cimcool of up to an aggregate of $26.0 based on multiple earn-out provisions. The Company accounts for contingent consideration under a loss recovery approach. Under a loss recovery approach, the Company records a contingent consideration asset only to the extent of the lesser of (1) the amount that the non-contingent consideration received is exceeded by the net assets deconsolidated, or (2) the amount of contingent consideration that it is probable will be received. As of the transaction date (and at March 31, 2020), the Company was unable to determine that it was probable that any of the contingent consideration would be received, and accordingly no asset was recorded for contingent consideration. Subsequent measurement of contingent consideration will be based on the guidance for gain contingencies and any gain from contingent consideration will be recorded at the time the consideration is received.
As a result of the sale, the Company recorded a pre-tax loss of $3.0, using Level 2 nonrecurring fair value measurements, within other (expense) income, net in the Consolidated Statements of Operations during the three and six months ended March 31, 2020. The related tax effect resulted in tax expense of $13.0 and was included within income tax expense (benefit) in the Consolidated Statements of Operations during the three and six months ended March 31, 2020. The Company incurred $3.8 of transaction costs associated with the sale during the three and six months ended March 31, 2020, which were recorded within operating expenses in the Consolidated Statements of Operations.
The Company determined that the sale of Cimcool did not represent a strategic shift that had or will have a major effect on its consolidated operations and financial results, and therefore Cimcool was not classified as a discontinued operation. Cimcool’s results of operations were included within the Milacron reportable segment until the completion of the sale on March 30, 2020.
Acquisition of Burnaby Machine and Mill Equipment Ltd.
The Company completed the acquisition of Burnaby Machine and Mill Equipment Ltd. (“BM&M”) in November 2018 for $26.2 in cash, which included post-closing working capital adjustments. The Company used its revolving credit facility to fund the acquisition. Based in Canada, BM&M provides high-speed gyratory screeners for a variety of industries. The results of BM&M are reported in the Process Equipment Group reportable segment.
|
|
5.
|
Supplemental Consolidated Balance Sheet Information
|
|
|
|
|
|
|
|
|
|
|
March 31,
2020
|
|
September 30,
2019
|
Trade accounts receivable reserves
|
$
|
24.6
|
|
|
$
|
22.8
|
|
|
|
|
|
Accumulated depreciation on property, plant, and equipment
|
$
|
322.3
|
|
|
$
|
309.0
|
|
|
|
|
|
Inventories, net:
|
|
|
|
|
|
Finished goods
|
$
|
184.0
|
|
|
$
|
60.3
|
|
Raw materials and components
|
138.0
|
|
|
72.3
|
|
Work in process
|
101.3
|
|
|
44.0
|
|
Total inventories, net
|
$
|
423.3
|
|
|
$
|
176.6
|
|
Trade accounts receivable reserves consist of the allowance of doubtful accounts, which is a best estimate of the amount of probable credit losses and collection risk in the existing trade receivables portfolio, and the allowance for cash discounts and sales returns, which is based upon historical experience and trends. The Company considers a variety of factors when determining the accounts receivable reserves including macroeconomic conditions, specific industry trends, and customer classes. The Company specifically considered the impact of the COVID-19 pandemic on our trade receivables and determined there was no material impact on existing trade receivables at March 31, 2020.
The Company’s lease portfolio is comprised of operating leases primarily for manufacturing facilities, offices, vehicles, and certain equipment. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on whether the contract conveys the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration. Leases are classified as operating or finance leases at the commencement date of the lease. Operating leases are recorded within operating lease right-of-use assets, other current liabilities, and operating lease liabilities in the Consolidated Balance Sheets. The Company’s finance leases were insignificant as of March 31, 2020. Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. We have elected an accounting policy to combine lease and non-lease components for all leases.
Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the implicit rate is generally not readily determinable for most leases, the Company uses an incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate reflects the estimated rate of interest that the Company would pay to borrow on a collateralized basis over a similar term in a similar economic environment. Lease expense for operating leases is recognized on a straight-line basis over the lease term.
Leases may include renewal options, and the renewal option is included in the lease term if the Company concludes that it is reasonably certain that the option will be exercised. A certain number of the Company’s leases contain rent escalation clauses, either fixed or adjusted periodically for inflation of market rates, that are factored into the calculation of lease payments to the extent they are fixed and determinable at lease inception. The Company also has variable lease payments that do not depend on a rate or index, primarily for items such as common area maintenance and real estate taxes, which are recorded as variable costs when incurred.
For the three and six months ended March 31, 2020, the Company recognized $9.8 and $17.8, respectively, of operating lease expense, including short-term lease expense and variable lease costs, which were immaterial in both periods.
The following table presents supplemental Consolidated Balance Sheet information related to the Company’s operating leases:
|
|
|
|
|
|
March 31, 2020
|
Operating lease right-of-use assets
|
$
|
165.0
|
|
|
|
Other current liabilities
|
$
|
31.7
|
|
Operating lease liabilities
|
130.8
|
|
Total operating lease liabilities
|
$
|
162.5
|
|
|
|
Weighted-average remaining lease term (in years)
|
7.8
|
|
|
|
Weighted-average discount rate
|
2.1
|
%
|
As of March 31, 2020, the maturities of the Company’s operating lease liabilities were as follows:
|
|
|
|
|
2020 (excluding the six months ended March 31, 2020)
|
$
|
17.3
|
|
2021
|
32.6
|
|
2022
|
28.1
|
|
2023
|
23.0
|
|
2024
|
15.6
|
|
Thereafter
|
57.0
|
|
Total lease payments
|
173.6
|
|
Less: imputed interest
|
(11.1
|
)
|
Total present value of lease payments
|
$
|
162.5
|
|
Supplemental Consolidated Statement of Cash Flow information is as follows:
|
|
|
|
|
|
|
|
Six Months Ended March 31, 2020
|
Cash paid for amounts included in the measurement of operating lease liabilities
|
|
$
|
18.0
|
|
Operating lease right-of-use assets obtained in exchange for new operating lease liabilities
|
|
18.7
|
|
|
|
7.
|
Intangible Assets and Goodwill
|
Impairment assessment
Impairment recorded during the period
Testing for impairment of goodwill and indefinite lived assets must be performed annually, or on an interim basis upon the occurrence of triggering events or substantive changes in circumstances that indicate that the fair value of the asset or reporting unit may have decreased below the carrying value. The Company’s annual assessment is performed at the reporting unit level, which consists of determining each reporting unit’s current fair value compared to its current carrying value. In connection with the preparation of the Consolidated Financial Statements for the three months ended March 31, 2020, an interim impairment assessment was performed for select reporting units within the Process Equipment Group and Milacron reportable segments as a result of certain triggering events and changes in circumstances discussed in detail below. Additionally, based on the macroeconomic factors below, as well as the decline in the Company’s common stock price during the three months ended March 31, 2020, the Company performed a qualitative review for all remaining reporting units and determined that those reporting units did not require an interim impairment test as it was more likely than not that the current fair value of those reporting units exceeded their carrying value, based on their current and projected financial performance as well as the headroom from previous goodwill impairment tests.
For certain reporting units within the Process Equipment Group reportable segment, an interim impairment review was triggered by the Company’s decision to redirect its strategic investments as it remains focused on deleveraging following two major events within the six months ended March 31, 2020: (1) the continued evaluation of the Company’s operations following the acquisition of Milacron completed on November 21, 2019, and (2) current adverse macroeconomic conditions primarily driven by the COVID-19 pandemic. In connection with these events, the Company has made the decision to limit its future strategic investment in its two reporting units that primarily sell and manufacture products in the flow control sector. The decision to limit future
investment as well as the Company’s updated forecasts, which considered the impact of the COVID-19 pandemic, reduced those reporting units’ anticipated annual revenue growth rates and corresponding profitability and cash flows. The annual revenue growth rates utilized in the Company’s fair value estimate are consistent with the reporting units’ operating plans. As a result of the change to expected future cash flows, along with comparable fair value information, the Company concluded that the carrying value for these reporting units exceeded their fair value, resulting in goodwill impairment charges of $72.3 during the three and six months ended March 31, 2020. The pre-impairment goodwill balance for these reporting units was $95.2. A 10% further reduction in the fair value of these reporting units would indicate a potential additional goodwill impairment of approximately $12.0. Additionally, under the relief-from-royalty fair value method, the Company concluded that the carrying value of a trade name associated with one of these reporting units exceeded its fair value. As a result, an impairment charge of $0.7 was recorded for this trade name during the three and six months ended March 31, 2020. The pre-impairment balance for this trade name was $4.4.
For the reporting units within the Milacron reportable segment, an interim impairment review was triggered by recent macroeconomic conditions primarily driven by the COVID-19 pandemic. Subsequent to the Company completing the acquisition of Milacron on November 21, 2019, the Company has since revised its forecasts for all reporting units within the Milacron reportable segment due to the deterioration in the overall global economy as a result of the pandemic. As a result of the decline in forecasted revenues, under the relief-from-royalty fair value method, the Company concluded that the carrying value of certain trade names and technology associated with these reporting units exceeded their fair value. As a result, impairment charges of $9.5 were recorded for these intangible assets during the three and six months ended March 31, 2020. The pre-impairment balance for these intangible assets was $125.0. A 10% further reduction in the fair value of these intangible assets, caused by further declines in forecasted revenues and changes in the discount rate selected by the Company, would indicate a potential additional impairment of approximately $12.0.
The impairment charges to goodwill and the identifiable intangible assets were nondeductible for tax purposes. The following table summarizes the impairment charges recorded by the Company during the three and six months ended March 31, 2020:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impairment Charges
|
|
Process Equipment Group
|
|
Milacron
|
|
Total
|
Goodwill
|
$
|
72.3
|
|
|
$
|
—
|
|
|
$
|
72.3
|
|
Trade names
|
0.7
|
|
|
7.9
|
|
|
8.6
|
|
Technology, including patents
|
—
|
|
|
1.6
|
|
|
1.6
|
|
Total
|
$
|
73.0
|
|
|
$
|
9.5
|
|
|
$
|
82.5
|
|
Additionally, as a result of the Company’s revised forecasts driven by the COVID-19 pandemic for all reporting units within the Milacron reportable segment, the Company performed an interim impairment review for these reporting units during the three months ended March 31, 2020 and determined that no impairment of goodwill occurred as a result of this triggering event. The estimated fair value, as calculated, for all four reporting units within the Milacron reportable segment ranged from approximately 3% to 16% greater than their carrying value as of March 31, 2020.
The valuation used to test goodwill for impairment is dependent upon a number of significant estimates and assumptions, including macroeconomic conditions, growth rates, competitive activities, cost containment, achievement of synergy initiatives, margin expansion, and the Company's business plans. The Company believes these estimates and assumptions are reasonable. However, future changes in the judgments, assumptions and estimates that are used in the impairment testing for goodwill, including discount and tax rates or future cash flow projections, could result in significantly different estimates of the fair values. As a result of these factors and the limited cushion (or headroom as commonly referred) due to the recent acquisition of Milacron, goodwill for the reporting units within the Milacron reportable segment are more susceptible to impairment risk.
The Company is required to provide additional disclosures about fair value measurements as part of the Consolidated Financial Statements for each major category of assets and liabilities measured at fair value on a nonrecurring basis (including impairment assessments). Goodwill and intangible assets were valued using Level 3 inputs, which are unobservable by nature, and included internal estimates of future cash flows (income approach). Significant increases (decreases) in any of those unobservable inputs in isolation would result in a significantly higher (lower) fair value measurement.
The most significant assumptions used in the determination of the estimated fair value of the reporting units are the revenue and EBITDA growth rates (including terminal growth rates) and the discount rate. The terminal growth rate represents the rate at which the reporting unit is expected to grow beyond the shorter-term business planning period. The terminal growth rate utilized in the Company’s fair value estimate is consistent with the reporting unit operating plans and approximates expected long-term category market growth rates and inflation. The discount rate, which is consistent with a weighted-average cost of capital that is likely to
be expected by a market participant, is based upon industry required rates of return, including consideration of both debt and equity components of the capital structure. The discount rates may be impacted by adverse changes in the macroeconomic environment, specifically the COVID-19 pandemic, volatility in the equity and debt markets or other factors.
While the Company can implement and has implemented certain strategies to address these events, changes in operating plans or adverse changes in the future could reduce the underlying cash flows used to estimate reporting unit fair values and could result in a further decline in fair value that would trigger a future material impairment charge of the reporting units’ goodwill balance.
Intangible Assets
Intangible assets are stated at the lower of cost or fair value. With the exception of most trade names, intangible assets are amortized on a straight-line basis over periods ranging from three to 21 years, representing the period over which the Company expects to receive future economic benefits from these assets. The Company assesses the carrying value of most trade names annually, or more often if events or changes in circumstances indicate there may be an impairment.
The following table summarizes the carrying amounts and related accumulated amortization for intangible assets as of March 31, 2020 and September 30, 2019:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2020
|
|
September 30, 2019
|
|
Cost
|
|
Accumulated
Amortization
|
|
Cost
|
|
Accumulated
Amortization
|
Finite-lived assets:
|
|
|
|
|
|
|
|
|
|
|
|
Trade names
|
$
|
0.2
|
|
|
$
|
(0.2
|
)
|
|
$
|
0.2
|
|
|
$
|
(0.2
|
)
|
Customer relationships
|
943.0
|
|
|
(191.2
|
)
|
|
464.2
|
|
|
(169.2
|
)
|
Technology, including patents
|
156.0
|
|
|
(55.4
|
)
|
|
76.8
|
|
|
(49.4
|
)
|
Software
|
65.6
|
|
|
(54.2
|
)
|
|
58.7
|
|
|
(51.7
|
)
|
Backlog
|
10.0
|
|
|
(10.0
|
)
|
|
—
|
|
|
—
|
|
Other
|
0.1
|
|
|
(0.1
|
)
|
|
0.2
|
|
|
(0.2
|
)
|
|
1,174.9
|
|
|
(311.1
|
)
|
|
600.1
|
|
|
(270.7
|
)
|
Indefinite-lived assets:
|
|
|
|
|
|
|
|
|
|
|
|
Trade names
|
237.5
|
|
|
—
|
|
|
125.5
|
|
|
—
|
|
|
|
|
|
|
|
|
|
Total
|
$
|
1,412.4
|
|
|
$
|
(311.1
|
)
|
|
$
|
725.6
|
|
|
$
|
(270.7
|
)
|
The net change in intangible assets during the six months ended March 31, 2020 was driven primarily by the following:
|
|
•
|
the acquisition of Milacron, which included acquired intangible assets of $815.0;
|
|
|
•
|
the divestiture of Cimcool, which included divested gross intangible assets of $122.1;
|
|
|
•
|
impairment charges to intangible assets of $10.2;
|
|
|
•
|
normal amortization; and
|
|
|
•
|
foreign currency adjustments.
|
See Note 4 for further information on the acquisition of Milacron and the divestiture of Cimcool. Estimated amortization expense related to intangible assets for the next five years is: $71.3 in 2020 (includes six months actual and six months estimated), $65.2 in 2021, $64.2 in 2022, $63.7 in 2023, and $63.6 in 2024.
Goodwill
As discussed above, goodwill is not amortized but is tested for impairment at least annually, or on an interim basis upon the occurrence of triggering events or substantive changes in circumstances. Goodwill has been assigned to reporting units. The Company assesses the carrying value of goodwill annually, or more often if events or changes in circumstances indicate there may be impairment. Impairment testing is performed at a reporting unit level.
The following table summarizes the changes in the Company’s goodwill, by reportable segment, for the six months ended March 31, 2020:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Process
Equipment
Group
|
|
Milacron
|
|
Batesville
|
|
Total
|
Balance as of September 30, 2019
|
$
|
569.7
|
|
|
$
|
—
|
|
|
$
|
8.3
|
|
|
$
|
578.0
|
|
Acquisitions (1)
|
1.7
|
|
|
705.3
|
|
|
—
|
|
|
707.0
|
|
Divestiture (2)
|
—
|
|
|
(77.9
|
)
|
|
—
|
|
|
(77.9
|
)
|
Impairment charges
|
(72.3
|
)
|
|
—
|
|
|
—
|
|
|
(72.3
|
)
|
Foreign currency adjustments
|
4.6
|
|
|
(5.9
|
)
|
|
—
|
|
|
(1.3
|
)
|
Balance as of March 31, 2020 (3)
|
$
|
503.7
|
|
|
$
|
621.5
|
|
|
$
|
8.3
|
|
|
$
|
1,133.5
|
|
|
|
(1)
|
See Note 4 for further information on the acquisitions of Milacron and BM&M.
|
|
|
(2)
|
See Note 4 for further information on the divestiture of Cimcool.
|
|
|
(3)
|
There was accumulated goodwill impairment of $131.1 and $58.8 within the Process Equipment Group as of March 31, 2020 and September 30, 2019, respectively.
|
The following table summarizes Hillenbrand’s current and long-term debt as of the dates reported in the Consolidated Balance Sheets:
|
|
|
|
|
|
|
|
|
|
March 31,
2020
|
|
September 30,
2019
|
$900.0 revolving credit facility (excluding outstanding letters of credit)
|
$
|
537.6
|
|
|
$
|
—
|
|
$500.0 term loan facility (1)
|
492.3
|
|
|
—
|
|
$375.0 senior unsecured notes, net of discount (2)
|
370.4
|
|
|
370.1
|
|
$225.0 term loan facility (3)
|
221.8
|
|
|
—
|
|
$150.0 senior unsecured notes, net of discount (4)
|
149.9
|
|
|
149.7
|
|
$100.0 Series A Notes (5)
|
99.7
|
|
|
99.7
|
|
Other
|
1.6
|
|
|
—
|
|
Total debt
|
1,873.3
|
|
|
619.5
|
|
Less: current portion
|
46.7
|
|
|
—
|
|
Total long-term debt
|
$
|
1,826.6
|
|
|
$
|
619.5
|
|
|
|
(1)
|
Includes unamortized debt issuance costs of $1.5 at March 31, 2020.
|
|
|
(2)
|
Includes unamortized debt issuance costs of $4.0 and $4.3 at March 31, 2020 and September 30, 2019, respectively.
|
|
|
(3)
|
Includes unamortized debt issuance costs of $0.4 at March 31, 2020.
|
|
|
(4)
|
Includes unamortized debt issuance costs of $0.1 and $0.2 at March 31, 2020 and September 30, 2019, respectively.
|
|
|
(5)
|
Includes unamortized debt issuance costs of $0.3 at both March 31, 2020 and September 30, 2019.
|
The following table summarizes the scheduled maturities of long-term debt for 2020 through 2024:
|
|
|
|
|
|
Amount
|
2020 (remaining six months) (1)
|
$
|
177.2
|
|
2021
|
36.2
|
|
2022
|
54.4
|
|
2023
|
223.2
|
|
2024
|
587.6
|
|
|
|
(1)
|
Includes the $150.0 senior unsecured notes which mature in July 2020. Upon maturity, the Company expects to refinance the notes on a long-term basis. The Company has the intent and believes it has the ability to refinance the notes due to expected available borrowing capacity under the Revolver, although the financing source ultimately used to refinance the notes may be different. As such, these obligations continue to be classified as long-term debt within the Consolidated Balance Sheets.
|
Financing for Milacron Acquisition
Upon completing the acquisition of Milacron on November 21, 2019, Hillenbrand incurred borrowings under its two term loans in aggregate principal amounts of $500.0 and $225.0 (the “Term Loan Facilities”), which are provided for under the Company’s Third Amended and Restated Credit Agreement dated August 28, 2019 and subsequently amended on October 8, 2019 and January 10, 2020 (the “Credit Agreement”). The $500.0 term loan matures on the fifth anniversary of the date on which it was borrowed, subject to quarterly amortization payments (equal to 5% of the original principal amount of the term loan in each of years 1 and 2, 7.5% in each of years 3 and 4, and 10% in year 5) and the $225.0 term loan matures on the third anniversary of the date on which it was borrowed, subject to quarterly amortization payments (equal to 5% of the original principal amount of the term loan in each of years 1 and 2, and 7.5% in year 3). The $500.0 term loan accrues interest, at the Company’s option, at the LIBO Rate or the Alternate Base Rate (each as defined in the Credit Agreement) plus a margin based on the Company’s leverage ratio, ranging from 1.00% to 1.875% for term loans bearing interest at the LIBO Rate and 0.0% to 0.875% for term loans bearing interest at the Alternate Base Rate. The $225.0 term loan accrues interest, at the Company’s option, at the LIBO Rate or the Alternate Base Rate plus a margin based on the Company’s leverage ratio, ranging from 0.875% to 1.75% for term loans bearing interest at the LIBO Rate and 0.0% to 0.75% for term loans bearing interest at the Alternate Base Rate. For the three and six months ended March 31, 2020, the weighted average interest rates were 3.36% and 3.40%, respectively, for the $500.0 term loan and 3.23% and 3.27%, respectively, for the $225.0 term loan. Deferred financing costs of $2.0 are being amortized to interest expense over the respective terms of the Term Loan Facilities.
In addition to the Term Loan Facilities, Hillenbrand incurred $650.0 of additional borrowings from its revolving credit facility under the Credit Agreement (the “Revolver”) at the closing of the Milacron acquisition. The additional borrowings under the Term Loan Facilities and the Revolver, in addition to the $375.0 of senior unsecured notes issued during the quarter ended September 30, 2019, were used to pay a portion of the cash consideration in connection with the acquisition of Milacron, fees and expenses related to the acquisition, and to repay certain indebtedness of Milacron and its subsidiaries upon closing the acquisition.
With respect to the Revolver, the Company has made net repayments since the closing date of the acquisition of Milacron, resulting in an outstanding balance of $537.6 as of March 31, 2020. As of March 31, 2020, the Company had $8.3 in outstanding letters of credit issued and $354.1 of maximum borrowing capacity under the Revolver. $159.7 of this borrowing capacity was immediately available based on the Company’s most restrictive covenant at March 31, 2020. The weighted-average interest rates on borrowings under the Revolver were 2.84% and 2.88% for the three and six months ended March 31, 2020, respectively, and 2.73% and 2.57% for the same periods in the prior year, respectively. The weighted average facility fee was 0.25% and 0.21% for the three and six months ended March 31, 2020, respectively, and 0.12% and 0.11% for the same periods in the prior year, respectively.
Other credit arrangements
In the normal course of business, operating companies within the Process Equipment Group and Milacron reportable segments provide to certain customers bank guarantees and other credit arrangements in support of performance, warranty, advance payment, and other contractual obligations. This form of trade finance is customary in the industry and, as a result, the Company maintains adequate capacity to provide the guarantees. As of March 31, 2020, the Company had credit arrangements totaling $379.7, under which $277.0 was used for this purpose. These arrangements include the Company’s Syndicated Letter of Guarantee Facility (as amended, the “L/G Facility Agreement”) and other ancillary credit facilities. On January 10, 2020, the L/G Facility Agreement was amended to expand the size of the existing €150.0 facility by an additional €25.0.
Covenants related to current financing agreements
The Credit Agreement, the L/G Facility Agreement, and the Series A Notes pursuant to the Private Shelf Agreement, dated as of December 6, 2012 (as amended, the “Shelf Agreement”), contain the following financial covenants: a maximum ratio of Indebtedness (as defined in the agreements) to EBITDA (as further defined in the agreements, the “Leverage Ratio”) of 3.5 to 1.0 including the application of cash as a reduction of Indebtedness (subject to certain limitations); a maximum Leverage Ratio resulting from an acquisition in excess of $75.0 of 4.0 to 1.0 for a period of three consecutive quarters following such acquisition; and a minimum ratio of EBITDA (as defined in the agreements) to interest expense of 3.0 to 1.0.
On January 10, 2020, with a retroactive effective date of December 31, 2019, the Company amended the Credit Agreement, the L/G Facility Agreement, and the Shelf Agreement to, among other things, (i) increase the maximum permitted leverage ratio to (A) 4.50 to 1.00 for the quarters ending December 31, 2019 and March 31, 2020, (B) 4.25 to 1.00 for the quarter ending June 30, 2020, (C) 4.00 to 1.00 for the quarter ending September 30, 2020, (D) 3.75 to 1.00 for the quarter ending December 31, 2020, and (E) 3.50 to 1.00 for the quarter ending March 31, 2021 and each quarter ending thereafter and (ii) add additional pricing levels to compensate for the increase in permitted leverage ratios.
As of March 31, 2020, Hillenbrand was in compliance with all covenants under these agreements. Additionally, the Credit Agreement, the L/G Facility Agreement, and the Shelf Agreement provide the Company with the ability to sell assets and to incur debt at its international subsidiaries under certain conditions.
All obligations of the Company arising under the Credit Agreement, the $375.0 and $150.0 senior unsecured notes, the Series A Notes, and the L/G Facility Agreement are fully and unconditionally, and jointly and severally, guaranteed by certain of the Company’s domestic subsidiaries.
The Credit Agreement, the L/G Facility Agreement, and the Shelf Agreement each contain certain other customary covenants, representations and warranties and events of default. The indentures governing both the $375.0 and $150.0 senior unsecured notes do not limit the Company’s ability to incur additional indebtedness. They do, however, contain certain covenants that restrict the Company’s ability to incur secured debt and to engage in certain sale and leaseback transactions. The indentures also contain customary events of default. The indentures provide holders of the senior unsecured notes with remedies if the Company fails to perform specific obligations. As of March 31, 2020, Hillenbrand was in compliance with all covenants and there were no events of default.
Defined Benefit Plans
In connection with the Milacron acquisition, the Company acquired three noncontributory defined benefit plans for certain non-U.S. employees and retirees. One plan covers certain employees in the United Kingdom and the other two plans cover certain employees in Germany. The aggregate fair value of the liability assumed for these defined benefit plans was $30.7 at November 21, 2019. Contributions to these plans are expected to approximate benefit payments each year.
Components of net periodic pension cost included in the Consolidated Statements of Operations were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. Pension Benefits
|
|
Non-U.S. Pension Benefits
|
|
Three Months Ended March 31,
|
|
Three Months Ended March 31,
|
|
2020
|
|
2019
|
|
2020
|
|
2019
|
Service costs
|
$
|
0.3
|
|
|
$
|
0.6
|
|
|
$
|
0.5
|
|
|
$
|
0.4
|
|
Interest costs
|
2.0
|
|
|
2.5
|
|
|
0.1
|
|
|
0.3
|
|
Expected return on plan assets
|
(3.2
|
)
|
|
(3.3
|
)
|
|
(0.2
|
)
|
|
(0.2
|
)
|
Amortization of unrecognized prior service costs, net
|
—
|
|
|
0.1
|
|
|
—
|
|
|
—
|
|
Amortization of net loss
|
1.2
|
|
|
0.2
|
|
|
0.9
|
|
|
0.3
|
|
Net periodic pension cost
|
$
|
0.3
|
|
|
$
|
0.1
|
|
|
$
|
1.3
|
|
|
$
|
0.8
|
|
|
|
|
|
|
|
|
|
|
U.S. Pension Benefits
|
|
Non-U.S. Pension Benefits
|
|
Six Months Ended March 31,
|
|
Six Months Ended March 31,
|
|
2020
|
|
2019
|
|
2020
|
|
2019
|
Service costs
|
$
|
0.7
|
|
|
$
|
1.2
|
|
|
$
|
1.1
|
|
|
$
|
0.7
|
|
Interest costs
|
4.0
|
|
|
5.1
|
|
|
0.3
|
|
|
0.6
|
|
Expected return on plan assets
|
(6.4
|
)
|
|
(6.6
|
)
|
|
(0.3
|
)
|
|
(0.3
|
)
|
Amortization of unrecognized prior service costs, net
|
—
|
|
|
0.1
|
|
|
—
|
|
|
—
|
|
Amortization of net loss
|
2.4
|
|
|
0.4
|
|
|
1.3
|
|
|
0.5
|
|
Net periodic pension cost
|
$
|
0.7
|
|
|
$
|
0.2
|
|
|
$
|
2.4
|
|
|
$
|
1.5
|
|
Defined Contribution Plans
In connection with the Milacron acquisition, the Company assumed a defined contribution plan (the “401(k) Plan”) for eligible U.S. employees and defined contribution plans for eligible employees at certain foreign subsidiaries. For the 401(k) Plan, eligible employees are permitted to contribute a percentage of their compensation and employees are immediately vested in their voluntary contributions. The Company’s contributions to the 401(k) Plan are based on matching a portion of the employee contributions and employees become vested in the Company contributions once they attain a year of credited service. For the assumed foreign plans, employees are immediately vested in both their voluntary and company matching contributions.
Expenses related to the Company’s defined contribution plans were $3.8 and $7.1 for the three and six months ended March 31, 2020, respectively, and $2.9 and $5.7 for the same periods in the prior year, respectively.
The effective tax rates for the three months ended March 31, 2020 and 2019 were (2.6%) and 25.9%, respectively. The negative effective tax rate in the current quarter and the difference from the prior year is due to the current quarter loss position and the discrete recognition of tax expense on the divestiture of Cimcool, which provided a decrease in the effective tax rate.
The effective tax rates for the six months ended March 31, 2020 and 2019 were 12.7% and 29.2%, respectively. Due to the current year net loss position, the effective tax rate decreased over the prior year as a result of the discrete recognition of tax expense on the divestiture of Cimcool, partially offset by the tax benefit recognized in 2020 from the revaluation of current and deferred tax balances in connection with the enacted statutory tax rate reductions in certain foreign jurisdictions. The change in the effective tax rate compared to the prior year was also impacted by the prior year increase in the reserve for unrecognized tax benefits that did not recur in the current year.
The acquisition of Milacron was completed as a taxable acquisition of the outstanding common stock of Milacron. In connection with the acquisition, the Company recorded a net deferred tax liability of $138.0 associated with the difference between the financial accounting basis and the tax basis in the acquired assets and liabilities assumed. Included in the acquired deferred taxes were deferred tax assets for the carryforward of Milacron’s tax net operating losses from federal, state, and foreign tax jurisdictions of $65.1, which were partially offset by the recognition of preliminary valuation allowances of $25.6 related to the estimated realizability of these items. The utilization of the acquired U.S. federal and state net operating losses to reduce Hillenbrand’s taxable income will be limited annually under Section 382 of the Internal Revenue Code. The Section 382 limitation analysis is in process as part of purchase accounting finalization and was not completed as of March 31, 2020. Additionally, Hillenbrand incurred transaction costs of $0.3 and $43.2 during the three and six months ended March 31, 2020, respectively, associated with the acquisition of Milacron. A preliminary estimate of the nondeductible portion of these costs has been determined to be approximately $24.9 and recognized as an adjustment to the forecasted tax rate for the year. As the Company continues to analyze the tax attributes of the acquisition, it will revise these preliminary estimates and appropriately record the impact of any changes in estimates.
The dilutive effects of performance-based stock awards were included in the computation of diluted earnings per share at the level the related performance criteria were met through the respective balance sheet date. Potential dilutive effects, representing approximately 400,000 shares at both March 31, 2020 and 2019, were excluded from the computation of diluted earnings per share as the related performance criteria were not yet met, although the Company expects to meet various levels of criteria in the future.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
March 31,
|
|
Six Months Ended
March 31,
|
|
2020
|
|
2019
|
|
2020
|
|
2019
|
Net (loss) income attributable to Hillenbrand
|
$
|
(74.0
|
)
|
|
$
|
38.0
|
|
|
$
|
(77.1
|
)
|
|
$
|
66.3
|
|
Weighted-average shares outstanding (basic - in millions) (1)
|
75.1
|
|
|
62.9
|
|
|
71.7
|
|
|
62.9
|
|
Effect of dilutive stock options and other unvested equity awards (in millions) (2)
|
—
|
|
|
0.5
|
|
|
—
|
|
|
0.5
|
|
Weighted-average shares outstanding (diluted - in millions)
|
75.1
|
|
|
63.4
|
|
|
71.7
|
|
|
63.4
|
|
|
|
|
|
|
|
|
|
Basic (loss) earnings per share
|
$
|
(0.99
|
)
|
|
$
|
0.60
|
|
|
$
|
(1.07
|
)
|
|
$
|
1.05
|
|
Diluted (loss) earnings per share
|
$
|
(0.99
|
)
|
|
$
|
0.60
|
|
|
$
|
(1.07
|
)
|
|
$
|
1.05
|
|
|
|
|
|
|
|
|
|
Shares with anti-dilutive effect excluded from the computation of diluted earnings per share (in millions)
|
3.1
|
|
|
1.1
|
|
|
2.8
|
|
|
0.9
|
|
|
|
(1)
|
The increase in weighted-average shares outstanding during the six months ended March 31, 2020 was due to 11.9 million of additional shares issued on November 21, 2019 in connection with the acquisition of Milacron. See Note 4 for further information.
|
|
|
(2)
|
As a result of the net loss attributable to Hillenbrand during the three and six months ended March 31, 2020, the effect of stock options and other unvested equity awards would be antidilutive. In accordance with GAAP, they have been excluded from the diluted earnings per share calculation.
|
|
|
12.
|
Accumulated Other Comprehensive Loss
|
The following tables summarize the changes in the accumulated balances for each component of accumulated other comprehensive loss:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension and
Postretirement
|
|
Currency
Translation
|
|
Net
Unrealized
Gain (Loss)
on Derivative
Instruments
|
|
Total
Attributable
to
Hillenbrand,
Inc.
|
|
Noncontrolling
Interests
|
|
Total
|
Balance at September 30, 2019
|
$
|
(62.3
|
)
|
|
$
|
(64.7
|
)
|
|
$
|
(13.6
|
)
|
|
$
|
(140.6
|
)
|
|
|
|
|
|
|
Other comprehensive loss before reclassifications:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Before tax amount
|
—
|
|
|
(12.3
|
)
|
|
(3.0
|
)
|
|
(15.3
|
)
|
|
$
|
(0.6
|
)
|
|
$
|
(15.9
|
)
|
Tax benefit
|
—
|
|
|
—
|
|
|
0.6
|
|
|
0.6
|
|
|
—
|
|
|
0.6
|
|
After tax amount
|
—
|
|
|
(12.3
|
)
|
|
(2.4
|
)
|
|
(14.7
|
)
|
|
(0.6
|
)
|
|
(15.3
|
)
|
Amounts reclassified from accumulated other comprehensive loss(1)
|
2.5
|
|
|
—
|
|
|
0.5
|
|
|
3.0
|
|
|
—
|
|
|
3.0
|
|
Net current period other comprehensive income (loss)
|
2.5
|
|
|
(12.3
|
)
|
|
(1.9
|
)
|
|
(11.7
|
)
|
|
$
|
(0.6
|
)
|
|
$
|
(12.3
|
)
|
Reclassification of certain income tax effects (2)
|
(6.0
|
)
|
|
—
|
|
|
—
|
|
|
(6.0
|
)
|
|
|
|
|
Balance at March 31, 2020
|
$
|
(65.8
|
)
|
|
$
|
(77.0
|
)
|
|
$
|
(15.5
|
)
|
|
$
|
(158.3
|
)
|
|
|
|
|
|
|
|
|
(1)
|
Amounts are net of tax.
|
|
|
(2)
|
Income tax effects of the Tax Act were reclassified from accumulated other comprehensive loss to retained earnings due to the adoption of ASU 2018-02. See Note 2 for more information.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension and
Postretirement
|
|
Currency
Translation
|
|
Net
Unrealized
Gain (Loss)
on Derivative
Instruments
|
|
Total
Attributable
to
Hillenbrand,
Inc.
|
|
Noncontrolling
Interests
|
|
Total
|
Balance at September 30, 2018
|
$
|
(41.0
|
)
|
|
$
|
(44.1
|
)
|
|
$
|
0.9
|
|
|
$
|
(84.2
|
)
|
|
|
|
|
|
|
Other comprehensive (loss) income before reclassifications:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Before tax amount
|
—
|
|
|
(9.7
|
)
|
|
(11.0
|
)
|
|
(20.7
|
)
|
|
$
|
0.2
|
|
|
$
|
(20.5
|
)
|
Tax benefit
|
—
|
|
|
—
|
|
|
2.6
|
|
|
2.6
|
|
|
—
|
|
|
2.6
|
|
After tax amount
|
—
|
|
|
(9.7
|
)
|
|
(8.4
|
)
|
|
(18.1
|
)
|
|
0.2
|
|
|
(17.9
|
)
|
Amounts reclassified from accumulated other comprehensive loss(1)
|
0.5
|
|
|
—
|
|
|
—
|
|
|
0.5
|
|
|
—
|
|
|
0.5
|
|
Net current period other comprehensive income (loss)
|
0.5
|
|
|
(9.7
|
)
|
|
(8.4
|
)
|
|
(17.6
|
)
|
|
$
|
0.2
|
|
|
$
|
(17.4
|
)
|
Balance at March 31, 2019
|
$
|
(40.5
|
)
|
|
$
|
(53.8
|
)
|
|
$
|
(7.5
|
)
|
|
$
|
(101.8
|
)
|
|
|
|
|
|
|
|
|
(1)
|
Amounts are net of tax.
|
Reclassifications out of accumulated other comprehensive loss include:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2020
|
|
Amortization of Pension and
Postretirement (1)
|
|
(Gain) Loss on
|
|
|
|
Net Loss
Recognized
|
|
Prior Service Costs
Recognized
|
|
Derivative
Instruments
|
|
Total
|
Affected Line in the Consolidated Statement of Operations:
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
(0.3
|
)
|
|
$
|
(0.3
|
)
|
Cost of goods sold
|
—
|
|
|
—
|
|
|
(0.2
|
)
|
|
(0.2
|
)
|
Other (expense) income, net
|
1.9
|
|
|
(0.1
|
)
|
|
0.5
|
|
|
2.3
|
|
Total before tax
|
$
|
1.9
|
|
|
$
|
(0.1
|
)
|
|
$
|
—
|
|
|
$
|
1.8
|
|
Tax benefit
|
|
|
|
|
|
|
(0.3
|
)
|
Total reclassifications for the period, net of tax
|
|
|
|
|
|
|
$
|
1.5
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended March 31, 2020
|
|
Amortization of Pension and
Postretirement (1)
|
|
(Gain) Loss on
|
|
|
|
Net Loss
Recognized
|
|
Prior Service Costs
Recognized
|
|
Derivative
Instruments
|
|
Total
|
Affected Line in the Consolidated Statement of Operations:
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
(0.2
|
)
|
|
$
|
(0.2
|
)
|
Cost of goods sold
|
—
|
|
|
—
|
|
|
(0.4
|
)
|
|
(0.4
|
)
|
Other (expense) income, net
|
3.5
|
|
|
(0.1
|
)
|
|
1.0
|
|
|
4.4
|
|
Total before tax
|
$
|
3.5
|
|
|
$
|
(0.1
|
)
|
|
$
|
0.4
|
|
|
$
|
3.8
|
|
Tax benefit
|
|
|
|
|
|
|
(0.8
|
)
|
Total reclassifications for the period, net of tax
|
|
|
|
|
|
|
$
|
3.0
|
|
|
|
(1)
|
These accumulated other comprehensive loss components are included in the computation of net periodic pension cost (see Note 9).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2019
|
|
Amortization of Pension and
Postretirement (1)
|
|
Loss (Gain) on
|
|
|
|
Net Loss
Recognized
|
|
Prior Service Costs
Recognized
|
|
Derivative
Instruments
|
|
Total
|
Affected Line in the Consolidated Statement of Operations:
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
0.1
|
|
|
$
|
0.1
|
|
Cost of goods sold
|
—
|
|
|
—
|
|
|
(0.1
|
)
|
|
(0.1
|
)
|
Other (expense) income, net
|
0.4
|
|
|
—
|
|
|
—
|
|
|
0.4
|
|
Total before tax
|
$
|
0.4
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
0.4
|
|
Tax benefit
|
|
|
|
|
|
|
|
|
|
(0.1
|
)
|
Total reclassifications for the period, net of tax
|
|
|
|
|
|
|
|
|
|
$
|
0.3
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended March 31, 2019
|
|
Amortization of Pension and
Postretirement (1)
|
|
(Gain)/Loss on
|
|
|
|
Net Loss
Recognized
|
|
Prior Service Costs
Recognized
|
|
Derivative
Instruments
|
|
Total
|
Affected Line in the Consolidated Statement of Operations:
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
0.2
|
|
|
$
|
0.2
|
|
Cost of goods sold
|
—
|
|
|
—
|
|
|
(0.2
|
)
|
|
(0.2
|
)
|
Other (expense) income, net
|
0.7
|
|
|
—
|
|
|
—
|
|
|
0.7
|
|
Total before tax
|
$
|
0.7
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
0.7
|
|
Tax benefit
|
|
|
|
|
|
|
(0.2
|
)
|
Total reclassifications for the period, net of tax
|
|
|
|
|
|
|
$
|
0.5
|
|
|
|
(1)
|
These accumulated other comprehensive loss components are included in the computation of net periodic pension cost (see Note 9).
|
|
|
13.
|
Share-Based Compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
March 31,
|
|
Six Months Ended
March 31,
|
|
2020
|
|
2019
|
|
2020
|
|
2019
|
Share-based compensation costs
|
$
|
3.4
|
|
|
$
|
3.9
|
|
|
$
|
5.7
|
|
|
$
|
5.8
|
|
Less impact of income tax benefit
|
0.8
|
|
|
0.9
|
|
|
1.3
|
|
|
1.3
|
|
Share-based compensation costs, net of tax
|
$
|
2.6
|
|
|
$
|
3.0
|
|
|
$
|
4.4
|
|
|
$
|
4.5
|
|
The Company has share-based compensation with long-term performance-based metrics that are contingent upon the Company’s relative total shareholder return and the creation of shareholder value. Relative total shareholder return is determined by comparing the Company’s total shareholder return during a three-year period to the respective total shareholder returns of companies in a designated performance peer group or stock index, as applicable. Creation of shareholder value is measured by the cumulative cash returns and final period net operating profit after tax compared to the established hurdle rate over a three-year period. For the performance-based awards contingent upon the creation of shareholder value, compensation expense is adjusted each quarter based upon actual results to date and any changes to forecasted information on each of the separate grants.
During the six months ended March 31, 2020, the Company made the following grants:
|
|
|
|
|
Number of
Units
|
Stock options
|
454,929
|
|
Time-based stock awards
|
315,555
|
|
Performance-based stock awards (maximum that can be earned)
|
423,651
|
|
Stock options granted during 2020 had a weighted-average exercise price of $31.94 and a weighted-average grant date fair value of $6.63. The Company’s time-based stock awards and performance-based stock awards granted during the six months ended March 31, 2020 had weighted-average grant date fair values of $31.63 and $32.74, respectively. Included in the performance-based stock awards granted during the six months ended March 31, 2020 are 252,406 units whose payout level is based upon the Company’s relative total shareholder return over the three-year measurement period, as described above. These units will be expensed on a straight-line basis over the measurement period and are not subsequently adjusted after the grant date.
|
|
14.
|
Other (Expense) Income, Net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
March 31,
|
|
Six Months Ended
March 31,
|
|
2020
|
|
2019
|
|
2020
|
|
2019
|
Net loss on divestiture
|
$
|
(3.0
|
)
|
|
$
|
—
|
|
|
$
|
(3.0
|
)
|
|
$
|
—
|
|
Interest income
|
0.6
|
|
|
—
|
|
|
1.9
|
|
|
—
|
|
Foreign currency exchange gain, net
|
1.8
|
|
|
0.1
|
|
|
1.9
|
|
|
0.5
|
|
Other, net
|
(0.1
|
)
|
|
—
|
|
|
0.4
|
|
|
0.1
|
|
Other (expense) income, net
|
$
|
(0.7
|
)
|
|
$
|
0.1
|
|
|
$
|
1.2
|
|
|
$
|
0.6
|
|
|
|
15.
|
Commitments and Contingencies
|
Like most companies, Hillenbrand is involved from time to time in claims, lawsuits, and government proceedings relating to its operations, including environmental, patent infringement, business practices, commercial transactions, product and general liability, workers’ compensation, auto liability, employment, and other matters. The ultimate outcome of these matters cannot be predicted with certainty. An estimated loss from these contingencies is recognized when the Company believes it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated; however, it is difficult to measure the actual loss that might be incurred related to these matters. If a loss is not considered probable and/or cannot be reasonably estimated, the Company is required to make a disclosure if there is at least a reasonable possibility that a significant loss may have been incurred. Legal fees associated with claims and lawsuits are generally expensed as incurred.
Claims covered by insurance have in most instances deductibles and self-funded retentions up to $0.5 per occurrence or per claim, depending upon the type of coverage and policy period. For auto, workers compensation, and general liability, outside insurance companies and third-party claims administrators generally assist in establishing individual claim reserves. An independent outside actuary provides estimates of ultimate projected losses, including incurred but not reported claims, which are used to establish reserves for losses. For all other types of claims, reserves are established based upon advice from internal and external counsel and historical settlement information for claims when such amounts are considered probable of payment.
The recorded amounts represent the best estimate of the costs that the Company will incur in relation to such exposures, but it is possible that actual costs will differ from those estimates.
|
|
16.
|
Fair Value Measurements
|
Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are from sources independent of the Company. Unobservable inputs reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability, developed based upon the best information available in the circumstances. The categorization of financial
assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels:
|
|
|
Level 1:
|
Inputs are quoted prices in active markets for identical assets or liabilities.
|
Level 2:
|
Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly.
|
Level 3:
|
Inputs are unobservable for the asset or liability.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Carrying Value at March 31, 2020
|
|
Fair Value at March 31, 2020
Using Inputs Considered as:
|
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
$
|
374.0
|
|
|
$
|
374.0
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Investments in rabbi trust
|
3.2
|
|
|
3.2
|
|
|
—
|
|
|
—
|
|
Derivative instruments
|
2.7
|
|
|
—
|
|
|
2.7
|
|
|
—
|
|
|
|
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
Revolver
|
537.6
|
|
|
—
|
|
|
537.6
|
|
|
—
|
|
$500.0 term loan facility
|
493.8
|
|
|
—
|
|
|
493.8
|
|
|
—
|
|
$375.0 senior unsecured notes
|
374.4
|
|
|
371.0
|
|
|
—
|
|
|
—
|
|
$225.0 term loan facility
|
222.2
|
|
|
—
|
|
|
222.2
|
|
|
—
|
|
$150.0 senior unsecured notes
|
150.0
|
|
|
149.1
|
|
|
—
|
|
|
—
|
|
$100.0 Series A Notes
|
100.0
|
|
|
—
|
|
|
98.9
|
|
|
—
|
|
Derivative instruments
|
6.3
|
|
|
—
|
|
|
6.3
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Carrying Value at September 30, 2019
|
|
Fair Value at September 30, 2019
Using Inputs Considered as:
|
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
$
|
399.0
|
|
|
$
|
399.0
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Investments in rabbi trust
|
4.2
|
|
|
4.2
|
|
|
—
|
|
|
—
|
|
Derivative instruments
|
2.5
|
|
|
—
|
|
|
2.5
|
|
|
—
|
|
|
|
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
$375.0 senior unsecured notes
|
374.4
|
|
|
380.6
|
|
|
—
|
|
|
—
|
|
$150.0 senior unsecured notes
|
149.9
|
|
|
152.8
|
|
|
—
|
|
|
—
|
|
$100.0 Series A Notes
|
100.0
|
|
|
—
|
|
|
108.5
|
|
|
—
|
|
Derivative instruments
|
2.6
|
|
|
—
|
|
|
2.6
|
|
|
—
|
|
Valuation Techniques
|
|
•
|
Cash and cash equivalents and investments in rabbi trust are classified within Level 1 of the fair value hierarchy. Financial instruments classified as Level 1 are based on quoted market prices in active markets. The types of financial instruments the Company classifies within Level 1 include most bank deposits, money market securities, and publicly traded mutual funds. The Company does not adjust the quoted market price for such financial instruments.
|
|
|
•
|
The Company estimates the fair value of foreign currency derivatives using industry accepted models. The significant Level 2 inputs used in the valuation of derivatives include spot rates, forward rates, and volatility. These inputs were obtained from pricing services, broker quotes, and other sources.
|
|
|
•
|
The fair value of the amounts outstanding under the Revolver and Term Loan Facilities approximate carrying value.
|
|
|
•
|
The fair values of the Series A Notes were estimated based on internally-developed models, using current market interest rate data for similar issues, as there is no active market for the Series A Notes.
|
|
|
•
|
The fair values of the $375.0 and $150.0 senior unsecured notes were based on quoted prices in active markets.
|
Derivative instruments
The Company has hedging programs in place to manage its currency exposures. The objectives of the Company’s hedging programs are to mitigate exposures in gross margin and non-functional-currency-denominated assets and liabilities. Under these programs, the Company uses derivative financial instruments to manage the economic impact of fluctuations in currency exchange rates. These include foreign currency exchange forward contracts, which generally have terms up to 24 months. The aggregate notional value of derivatives was $238.2 and $128.9 at March 31, 2020 and September 30, 2019, respectively. The derivatives are recorded at fair value primarily in other current assets and other current liabilities in the Consolidated Balance Sheets.
|
|
17.
|
Segment and Geographical Information
|
Prior to completing the acquisition of Milacron on November 21, 2019, the Company conducted operations through two reportable business segments: the Process Equipment Group and Batesville. Upon completing the acquisition, the Company has been undertaking a planning process of assessing its management and organizational structure. As of March 31, 2020, the Company is still assessing changes in its internal management reporting structure to incorporate Milacron and the effects it may have on the Company’s reportable segments, if any. Because this process was not complete as of March 31, 2020, the Company has reported the results of operations of Milacron from the acquisition date through March 31, 2020 as a separate reportable segment.
The Company records the direct costs of business operations to the reportable business segments, including stock-based compensation, asset impairments, restructuring activities, and business acquisition costs. Corporate provides management and administrative services to each reportable segment. These services include treasury management, human resources, legal, business development, and other public company support functions such as internal audit, investor relations, financial reporting, and tax compliance. With limited exception for certain professional services and back-office and technology costs, the Company does not allocate these types of corporate expenses to the reportable segments.
The following tables present financial information for the Company’s reportable segments and significant geographical locations:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31,
|
|
Six Months Ended March 31,
|
|
2020
|
|
2019
|
|
2020
|
|
2019
|
Net revenue
|
|
|
|
|
|
|
|
|
|
Process Equipment Group
|
$
|
311.1
|
|
|
$
|
326.7
|
|
|
$
|
617.7
|
|
|
$
|
608.9
|
|
Milacron
|
199.0
|
|
|
—
|
|
|
332.3
|
|
|
—
|
|
Batesville
|
138.8
|
|
|
137.9
|
|
|
265.8
|
|
|
266.0
|
|
Total
|
$
|
648.9
|
|
|
$
|
464.6
|
|
|
$
|
1,215.8
|
|
|
$
|
874.9
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA (1)
|
|
|
|
|
|
|
|
|
|
Process Equipment Group
|
$
|
57.5
|
|
|
$
|
55.5
|
|
|
$
|
109.0
|
|
|
$
|
101.7
|
|
Milacron
|
31.9
|
|
|
—
|
|
|
58.2
|
|
|
—
|
|
Batesville
|
32.0
|
|
|
31.6
|
|
|
55.0
|
|
|
58.3
|
|
Corporate
|
(10.8
|
)
|
|
(12.2
|
)
|
|
(19.7
|
)
|
|
(21.0
|
)
|
|
|
|
|
|
|
|
|
Net revenue (2)
|
|
|
|
|
|
|
|
|
|
United States
|
$
|
288.0
|
|
|
$
|
232.4
|
|
|
$
|
560.9
|
|
|
$
|
447.2
|
|
Germany
|
188.6
|
|
|
141.6
|
|
|
344.0
|
|
|
252.9
|
|
All other foreign business units
|
172.3
|
|
|
90.6
|
|
|
310.9
|
|
|
174.8
|
|
Total
|
$
|
648.9
|
|
|
$
|
464.6
|
|
|
$
|
1,215.8
|
|
|
$
|
874.9
|
|
|
|
(1)
|
Adjusted EBITDA is a non-GAAP measure used by management to measure segment performance and make operating decisions. See the Operating Performance Measures section of Management’s Discussion and Analysis for further information on adjusted EBITDA, which is reconciled to consolidated net (loss) income below.
|
|
|
(2)
|
The Company attributes net revenue to a geography based upon the location of the business that consummates the external sale.
|
|
|
|
|
|
|
|
|
|
|
March 31,
2020
|
|
September 30,
2019
|
Total assets assigned
|
|
|
|
|
|
Process Equipment Group
|
$
|
1,736.7
|
|
|
$
|
1,729.1
|
|
Milacron
|
2,001.3
|
|
|
—
|
|
Batesville
|
233.7
|
|
|
186.1
|
|
Corporate
|
219.0
|
|
|
313.4
|
|
Total
|
$
|
4,190.7
|
|
|
$
|
2,228.6
|
|
|
|
|
|
Tangible long-lived assets, net(1)
|
|
|
|
|
|
United States
|
$
|
218.1
|
|
|
$
|
75.8
|
|
Germany
|
105.6
|
|
|
40.2
|
|
China
|
51.4
|
|
|
4.4
|
|
All other foreign business units
|
138.6
|
|
|
19.9
|
|
Total
|
$
|
513.7
|
|
|
$
|
140.3
|
|
|
|
(1)
|
Tangible long-lived assets, net includes operating lease right-of-use assets as of March 31, 2020 due to the adoption of ASU 2016-02 in the current year.
|
The following schedule reconciles reportable segment adjusted EBITDA to consolidated net (loss) income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
March 31,
|
|
Six Months Ended
March 31,
|
|
2020
|
|
2019
|
|
2020
|
|
2019
|
Adjusted EBITDA:
|
|
|
|
|
|
|
|
Process Equipment Group
|
$
|
57.5
|
|
|
$
|
55.5
|
|
|
$
|
109.0
|
|
|
$
|
101.7
|
|
Milacron
|
31.9
|
|
|
—
|
|
|
58.2
|
|
|
—
|
|
Batesville
|
32.0
|
|
|
31.6
|
|
|
55.0
|
|
|
58.3
|
|
Corporate
|
(10.8
|
)
|
|
(12.2
|
)
|
|
(19.7
|
)
|
|
(21.0
|
)
|
Less:
|
|
|
|
|
|
|
|
|
|
Interest income
|
(0.6
|
)
|
|
(0.2
|
)
|
|
(1.9
|
)
|
|
(0.4
|
)
|
Interest expense
|
20.9
|
|
|
5.4
|
|
|
35.6
|
|
|
10.9
|
|
Income tax expense (benefit)
|
1.8
|
|
|
13.8
|
|
|
(10.6
|
)
|
|
28.3
|
|
Depreciation and amortization
|
38.6
|
|
|
15.1
|
|
|
64.5
|
|
|
29.2
|
|
Impairment charges
|
82.5
|
|
|
—
|
|
|
82.5
|
|
|
—
|
|
Business acquisition, disposition, and integration costs
|
8.0
|
|
|
0.5
|
|
|
61.8
|
|
|
1.1
|
|
Restructuring and restructuring-related charges
|
0.7
|
|
|
0.7
|
|
|
3.1
|
|
|
1.2
|
|
Inventory step-up
|
27.5
|
|
|
0.1
|
|
|
37.1
|
|
|
0.2
|
|
Net loss on divestiture
|
3.0
|
|
|
—
|
|
|
3.0
|
|
|
—
|
|
Other
|
0.4
|
|
|
—
|
|
|
0.4
|
|
|
—
|
|
Consolidated net (loss) income
|
$
|
(72.2
|
)
|
|
$
|
39.5
|
|
|
$
|
(73.0
|
)
|
|
$
|
68.5
|
|
|
|
18.
|
Condensed Consolidating Information
|
Certain 100% owned domestic subsidiaries of Hillenbrand fully and unconditionally, jointly and severally, agreed to guarantee all of the indebtedness and guarantee obligations relating to obligations under its senior unsecured notes. The following are the condensed consolidating financial statements, including the guarantors, which present the statements of operations, balance sheets, and cash flows of (i) the parent holding company, (ii) the guarantor subsidiaries, (iii) the non-guarantor subsidiaries, and (iv) eliminations necessary to present the information for Hillenbrand on a consolidated basis.
Condensed Consolidating Statements of Operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2020
|
|
Three Months Ended March 31, 2019
|
|
Parent
|
|
Guarantors
|
|
Non-
Guarantors
|
|
Eliminations
|
|
Consolidated
|
|
Parent
|
|
Guarantors
|
|
Non-
Guarantors
|
|
Eliminations
|
|
Consolidated
|
Net revenue
|
$
|
—
|
|
|
$
|
212.6
|
|
|
$
|
493.2
|
|
|
$
|
(56.9
|
)
|
|
$
|
648.9
|
|
|
$
|
—
|
|
|
$
|
230.6
|
|
|
$
|
294.1
|
|
|
$
|
(60.1
|
)
|
|
$
|
464.6
|
|
Cost of goods sold
|
—
|
|
|
117.2
|
|
|
367.8
|
|
|
(29.8
|
)
|
|
455.2
|
|
|
—
|
|
|
126.8
|
|
|
210.0
|
|
|
(33.1
|
)
|
|
303.7
|
|
Gross profit
|
—
|
|
|
95.4
|
|
|
125.4
|
|
|
(27.1
|
)
|
|
193.7
|
|
|
—
|
|
|
103.8
|
|
|
84.1
|
|
|
(27.0
|
)
|
|
160.9
|
|
Operating expenses
|
15.0
|
|
|
57.6
|
|
|
90.5
|
|
|
(27.1
|
)
|
|
136.0
|
|
|
13.7
|
|
|
60.9
|
|
|
46.1
|
|
|
(27.0
|
)
|
|
93.7
|
|
Amortization expense
|
—
|
|
|
3.4
|
|
|
20.6
|
|
|
—
|
|
|
24.0
|
|
|
—
|
|
|
3.4
|
|
|
5.2
|
|
|
—
|
|
|
8.6
|
|
Impairment charges
|
—
|
|
|
54.7
|
|
|
27.8
|
|
|
—
|
|
|
82.5
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Interest expense
|
0.3
|
|
|
0.2
|
|
|
20.4
|
|
|
—
|
|
|
20.9
|
|
|
4.7
|
|
|
0.1
|
|
|
0.6
|
|
|
—
|
|
|
5.4
|
|
Other (expense) income, net
|
(0.5
|
)
|
|
(0.7
|
)
|
|
0.5
|
|
|
—
|
|
|
(0.7
|
)
|
|
(0.2
|
)
|
|
(0.1
|
)
|
|
0.4
|
|
|
—
|
|
|
0.1
|
|
Equity in net income of subsidiaries
|
(43.7
|
)
|
|
2.5
|
|
|
—
|
|
|
41.2
|
|
|
—
|
|
|
51.4
|
|
|
3.5
|
|
|
—
|
|
|
(54.9
|
)
|
|
—
|
|
(Loss) income before income taxes
|
(59.5
|
)
|
|
(18.7
|
)
|
|
(33.4
|
)
|
|
41.2
|
|
|
(70.4
|
)
|
|
32.8
|
|
|
42.8
|
|
|
32.6
|
|
|
(54.9
|
)
|
|
53.3
|
|
Income tax expense (benefit)
|
14.5
|
|
|
(5.2
|
)
|
|
(7.5
|
)
|
|
—
|
|
|
1.8
|
|
|
(5.2
|
)
|
|
10.6
|
|
|
8.4
|
|
|
—
|
|
|
13.8
|
|
Consolidated net (loss) income
|
(74.0
|
)
|
|
(13.5
|
)
|
|
(25.9
|
)
|
|
41.2
|
|
|
(72.2
|
)
|
|
38.0
|
|
|
32.2
|
|
|
24.2
|
|
|
(54.9
|
)
|
|
39.5
|
|
Less: Net income attributable to
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
noncontrolling interests
|
—
|
|
|
—
|
|
|
1.8
|
|
|
—
|
|
|
1.8
|
|
|
—
|
|
|
—
|
|
|
1.5
|
|
|
—
|
|
|
1.5
|
|
Net (loss) income attributable to Hillenbrand
|
$
|
(74.0
|
)
|
|
$
|
(13.5
|
)
|
|
$
|
(27.7
|
)
|
|
$
|
41.2
|
|
|
$
|
(74.0
|
)
|
|
$
|
38.0
|
|
|
$
|
32.2
|
|
|
$
|
22.7
|
|
|
$
|
(54.9
|
)
|
|
$
|
38.0
|
|
Consolidated comprehensive (loss) income
|
$
|
(105.6
|
)
|
|
$
|
(15.1
|
)
|
|
$
|
(55.3
|
)
|
|
$
|
71.7
|
|
|
$
|
(104.3
|
)
|
|
$
|
30.5
|
|
|
$
|
32.4
|
|
|
$
|
19.6
|
|
|
$
|
(50.5
|
)
|
|
$
|
32.0
|
|
Less: Comprehensive income attributable
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
to noncontrolling interests
|
—
|
|
|
—
|
|
|
1.3
|
|
|
—
|
|
|
1.3
|
|
|
—
|
|
|
—
|
|
|
1.5
|
|
|
—
|
|
|
1.5
|
|
Comprehensive (loss) income attributable to Hillenbrand
|
$
|
(105.6
|
)
|
|
$
|
(15.1
|
)
|
|
$
|
(56.6
|
)
|
|
$
|
71.7
|
|
|
$
|
(105.6
|
)
|
|
$
|
30.5
|
|
|
$
|
32.4
|
|
|
$
|
18.1
|
|
|
$
|
(50.5
|
)
|
|
$
|
30.5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended March 31, 2020
|
|
Six Months Ended March 31, 2019
|
|
Parent
|
|
Guarantors
|
|
Non-
Guarantors
|
|
Eliminations
|
|
Consolidated
|
|
Parent
|
|
Guarantors
|
|
Non-
Guarantors
|
|
Eliminations
|
|
Consolidated
|
Net revenue
|
$
|
—
|
|
|
$
|
418.1
|
|
|
$
|
910.2
|
|
|
$
|
(112.5
|
)
|
|
$
|
1,215.8
|
|
|
$
|
—
|
|
|
$
|
446.7
|
|
|
$
|
541.9
|
|
|
$
|
(113.7
|
)
|
|
$
|
874.9
|
|
Cost of goods sold
|
—
|
|
|
234.9
|
|
|
674.1
|
|
|
(58.7
|
)
|
|
850.3
|
|
|
—
|
|
|
242.6
|
|
|
384.4
|
|
|
(60.0
|
)
|
|
567.0
|
|
Gross profit
|
—
|
|
|
183.2
|
|
|
236.1
|
|
|
(53.8
|
)
|
|
365.5
|
|
|
—
|
|
|
204.1
|
|
|
157.5
|
|
|
(53.7
|
)
|
|
307.9
|
|
Operating expenses
|
63.6
|
|
|
116.1
|
|
|
167.5
|
|
|
(53.8
|
)
|
|
293.4
|
|
|
23.9
|
|
|
122.3
|
|
|
91.9
|
|
|
(53.7
|
)
|
|
184.4
|
|
Amortization expense
|
—
|
|
|
6.7
|
|
|
32.1
|
|
|
—
|
|
|
38.8
|
|
|
—
|
|
|
6.7
|
|
|
9.7
|
|
|
—
|
|
|
16.4
|
|
Impairment charges
|
—
|
|
|
54.7
|
|
|
27.8
|
|
|
—
|
|
|
82.5
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Interest expense
|
5.5
|
|
|
0.2
|
|
|
29.9
|
|
|
—
|
|
|
35.6
|
|
|
9.2
|
|
|
0.1
|
|
|
1.6
|
|
|
—
|
|
|
10.9
|
|
Other income (expense), net
|
0.4
|
|
|
(1.6
|
)
|
|
2.4
|
|
|
—
|
|
|
1.2
|
|
|
(0.5
|
)
|
|
(0.1
|
)
|
|
1.2
|
|
|
—
|
|
|
0.6
|
|
Equity in net income of subsidiaries
|
(18.1
|
)
|
|
4.3
|
|
|
—
|
|
|
13.8
|
|
|
—
|
|
|
93.4
|
|
|
5.7
|
|
|
—
|
|
|
(99.1
|
)
|
|
—
|
|
(Loss) income before income taxes
|
(86.8
|
)
|
|
8.2
|
|
|
(18.8
|
)
|
|
13.8
|
|
|
(83.6
|
)
|
|
59.8
|
|
|
80.6
|
|
|
55.5
|
|
|
(99.1
|
)
|
|
96.8
|
|
Income tax (benefit) expense
|
(9.7
|
)
|
|
1.0
|
|
|
(1.9
|
)
|
|
—
|
|
|
(10.6
|
)
|
|
(6.5
|
)
|
|
20.5
|
|
|
14.3
|
|
|
—
|
|
|
28.3
|
|
Consolidated net (loss) income
|
(77.1
|
)
|
|
7.2
|
|
|
(16.9
|
)
|
|
13.8
|
|
|
(73.0
|
)
|
|
66.3
|
|
|
60.1
|
|
|
41.2
|
|
|
(99.1
|
)
|
|
68.5
|
|
Less: Net income attributable to
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
noncontrolling interests
|
—
|
|
|
—
|
|
|
4.1
|
|
|
—
|
|
|
4.1
|
|
|
—
|
|
|
—
|
|
|
2.2
|
|
|
—
|
|
|
2.2
|
|
Net (loss) income attributable to Hillenbrand
|
$
|
(77.1
|
)
|
|
$
|
7.2
|
|
|
$
|
(21.0
|
)
|
|
$
|
13.8
|
|
|
$
|
(77.1
|
)
|
|
$
|
66.3
|
|
|
$
|
60.1
|
|
|
$
|
39.0
|
|
|
$
|
(99.1
|
)
|
|
$
|
66.3
|
|
Consolidated comprehensive (loss) income
|
$
|
(88.8
|
)
|
|
$
|
3.8
|
|
|
$
|
(29.4
|
)
|
|
$
|
29.1
|
|
|
$
|
(85.3
|
)
|
|
$
|
48.7
|
|
|
$
|
60.2
|
|
|
$
|
31.4
|
|
|
$
|
(89.2
|
)
|
|
$
|
51.1
|
|
Less: Comprehensive income attributable
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
to noncontrolling interests
|
—
|
|
|
—
|
|
|
3.5
|
|
|
—
|
|
|
3.5
|
|
|
—
|
|
|
—
|
|
|
2.4
|
|
|
—
|
|
|
2.4
|
|
Comprehensive (loss) income attributable to Hillenbrand
|
$
|
(88.8
|
)
|
|
$
|
3.8
|
|
|
$
|
(32.9
|
)
|
|
$
|
29.1
|
|
|
$
|
(88.8
|
)
|
|
$
|
48.7
|
|
|
$
|
60.2
|
|
|
$
|
29.0
|
|
|
$
|
(89.2
|
)
|
|
$
|
48.7
|
|
Condensed Consolidating Balance Sheets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2020
|
|
September 30, 2019
|
|
Parent
|
|
Guarantors
|
|
Non-
Guarantors
|
|
Eliminations
|
|
Consolidated
|
|
Parent
|
|
Guarantors
|
|
Non-
Guarantors
|
|
Eliminations
|
|
Consolidated
|
Cash and cash equivalents
|
$
|
145.3
|
|
|
$
|
11.5
|
|
|
$
|
217.2
|
|
|
$
|
—
|
|
|
$
|
374.0
|
|
|
$
|
283.1
|
|
|
$
|
9.6
|
|
|
$
|
106.3
|
|
|
$
|
—
|
|
|
$
|
399.0
|
|
Trade receivables, net
|
—
|
|
|
92.3
|
|
|
200.5
|
|
|
—
|
|
|
292.8
|
|
|
—
|
|
|
113.6
|
|
|
103.8
|
|
|
—
|
|
|
217.4
|
|
Receivables from long-term manufacturing contracts
|
—
|
|
|
13.2
|
|
|
174.1
|
|
|
—
|
|
|
187.3
|
|
|
—
|
|
|
9.8
|
|
|
171.3
|
|
|
—
|
|
|
181.1
|
|
Inventories, net
|
—
|
|
|
78.2
|
|
|
347.9
|
|
|
(2.8
|
)
|
|
423.3
|
|
|
—
|
|
|
78.2
|
|
|
101.2
|
|
|
(2.8
|
)
|
|
176.6
|
|
Intercompany receivables
|
—
|
|
|
1,135.2
|
|
|
149.9
|
|
|
(1,285.1
|
)
|
|
—
|
|
|
—
|
|
|
1,179.7
|
|
|
—
|
|
|
(1,179.7
|
)
|
|
—
|
|
Prepaid expenses and other current assets
|
4.6
|
|
|
25.3
|
|
|
54.8
|
|
|
2.0
|
|
|
86.7
|
|
|
2.5
|
|
|
6.1
|
|
|
40.1
|
|
|
0.4
|
|
|
49.1
|
|
Total current assets
|
149.9
|
|
|
1,355.7
|
|
|
1,144.4
|
|
|
(1,285.9
|
)
|
|
1,364.1
|
|
|
285.6
|
|
|
1,397.0
|
|
|
522.7
|
|
|
(1,182.1
|
)
|
|
1,023.2
|
|
Property, plant and equipment, net
|
3.7
|
|
|
60.8
|
|
|
284.2
|
|
|
—
|
|
|
348.7
|
|
|
3.8
|
|
|
61.2
|
|
|
75.3
|
|
|
—
|
|
|
140.3
|
|
Operating lease right-of-use assets
|
0.7
|
|
|
13.2
|
|
|
151.1
|
|
|
—
|
|
|
165.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Intangible assets, net
|
2.3
|
|
|
174.3
|
|
|
924.7
|
|
|
—
|
|
|
1,101.3
|
|
|
2.4
|
|
|
181.4
|
|
|
271.1
|
|
|
—
|
|
|
454.9
|
|
Goodwill
|
—
|
|
|
170.3
|
|
|
963.2
|
|
|
—
|
|
|
1,133.5
|
|
|
—
|
|
|
225.0
|
|
|
353.0
|
|
|
—
|
|
|
578.0
|
|
Investment in consolidated subsidiaries
|
3,947.1
|
|
|
654.1
|
|
|
—
|
|
|
(4,601.2
|
)
|
|
—
|
|
|
2,266.4
|
|
|
655.2
|
|
|
—
|
|
|
(2,921.6
|
)
|
|
—
|
|
Other long-term assets
|
49.9
|
|
|
27.4
|
|
|
27.7
|
|
|
(26.9
|
)
|
|
78.1
|
|
|
33.8
|
|
|
20.5
|
|
|
3.1
|
|
|
(25.2
|
)
|
|
32.2
|
|
Total Assets
|
$
|
4,153.6
|
|
|
$
|
2,455.8
|
|
|
$
|
3,495.3
|
|
|
$
|
(5,914.0
|
)
|
|
$
|
4,190.7
|
|
|
$
|
2,592.0
|
|
|
$
|
2,540.3
|
|
|
$
|
1,225.2
|
|
|
$
|
(4,128.9
|
)
|
|
$
|
2,228.6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trade accounts payable
|
$
|
3.9
|
|
|
$
|
60.4
|
|
|
$
|
233.6
|
|
|
$
|
—
|
|
|
$
|
297.9
|
|
|
$
|
2.6
|
|
|
$
|
59.0
|
|
|
$
|
174.6
|
|
|
$
|
—
|
|
|
$
|
236.2
|
|
Liabilities from long-term manufacturing contracts and advances
|
—
|
|
|
13.0
|
|
|
163.6
|
|
|
—
|
|
|
176.6
|
|
|
—
|
|
|
13.5
|
|
|
144.7
|
|
|
—
|
|
|
158.2
|
|
Current portion of long-term debt
|
45.3
|
|
|
—
|
|
|
1.4
|
|
|
—
|
|
|
46.7
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Accrued compensation
|
3.0
|
|
|
13.3
|
|
|
61.9
|
|
|
—
|
|
|
78.2
|
|
|
6.9
|
|
|
20.8
|
|
|
45.5
|
|
|
—
|
|
|
73.2
|
|
Intercompany payables
|
1,287.9
|
|
|
—
|
|
|
—
|
|
|
(1,287.9
|
)
|
|
—
|
|
|
1,167.0
|
|
|
10.2
|
|
|
5.3
|
|
|
(1,182.5
|
)
|
|
—
|
|
Other current liabilities
|
26.2
|
|
|
54.8
|
|
|
124.5
|
|
|
0.3
|
|
|
205.8
|
|
|
19.2
|
|
|
45.0
|
|
|
67.1
|
|
|
(9.6
|
)
|
|
121.7
|
|
Total current liabilities
|
1,366.3
|
|
|
141.5
|
|
|
585.0
|
|
|
(1,287.6
|
)
|
|
805.2
|
|
|
1,195.7
|
|
|
148.5
|
|
|
437.2
|
|
|
(1,192.1
|
)
|
|
589.3
|
|
Long-term debt
|
1,754.8
|
|
|
—
|
|
|
71.8
|
|
|
—
|
|
|
1,826.6
|
|
|
619.5
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
619.5
|
|
Accrued pension and postretirement healthcare
|
0.9
|
|
|
30.4
|
|
|
126.6
|
|
|
—
|
|
|
157.9
|
|
|
0.8
|
|
|
32.1
|
|
|
98.4
|
|
|
—
|
|
|
131.3
|
|
Operating lease liabilities
|
0.4
|
|
|
10.3
|
|
|
120.1
|
|
|
—
|
|
|
130.8
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Deferred income taxes
|
—
|
|
|
12.0
|
|
|
200.7
|
|
|
(25.2
|
)
|
|
187.5
|
|
|
—
|
|
|
24.0
|
|
|
64.8
|
|
|
(15.2
|
)
|
|
73.6
|
|
Other long-term liabilities
|
22.2
|
|
|
14.7
|
|
|
18.8
|
|
|
—
|
|
|
55.7
|
|
|
21.9
|
|
|
12.5
|
|
|
10.7
|
|
|
—
|
|
|
45.1
|
|
Total Liabilities
|
3,144.6
|
|
|
208.9
|
|
|
1,123.0
|
|
|
(1,312.8
|
)
|
|
3,163.7
|
|
|
1,837.9
|
|
|
217.1
|
|
|
611.1
|
|
|
(1,207.3
|
)
|
|
1,458.8
|
|
Hillenbrand Shareholders’ Equity
|
1,009.0
|
|
|
2,246.9
|
|
|
2,354.3
|
|
|
(4,601.2
|
)
|
|
1,009.0
|
|
|
754.1
|
|
|
2,323.2
|
|
|
598.4
|
|
|
(2,921.6
|
)
|
|
754.1
|
|
Noncontrolling interests
|
—
|
|
|
—
|
|
|
18.0
|
|
|
—
|
|
|
18.0
|
|
|
—
|
|
|
—
|
|
|
15.7
|
|
|
—
|
|
|
15.7
|
|
Total Shareholders’ Equity
|
1,009.0
|
|
|
2,246.9
|
|
|
2,372.3
|
|
|
(4,601.2
|
)
|
|
1,027.0
|
|
|
754.1
|
|
|
2,323.2
|
|
|
614.1
|
|
|
(2,921.6
|
)
|
|
769.8
|
|
Total Liabilities and Shareholders’ Equity
|
$
|
4,153.6
|
|
|
$
|
2,455.8
|
|
|
$
|
3,495.3
|
|
|
$
|
(5,914.0
|
)
|
|
$
|
4,190.7
|
|
|
$
|
2,592.0
|
|
|
$
|
2,540.3
|
|
|
$
|
1,225.2
|
|
|
$
|
(4,128.9
|
)
|
|
$
|
2,228.6
|
|
Condensed Consolidating Statements of Cash Flows
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended March 31, 2020
|
|
Six Months Ended March 31, 2019
|
|
Parent
|
|
Guarantors
|
|
Non-
Guarantors
|
|
Eliminations
|
|
Consolidated
|
|
Parent
|
|
Guarantors
|
|
Non-
Guarantors
|
|
Eliminations
|
|
Consolidated
|
Net cash provided by (used in)
operating activities
|
$
|
2.0
|
|
|
$
|
103.2
|
|
|
$
|
42.6
|
|
|
$
|
(102.5
|
)
|
|
$
|
45.3
|
|
|
$
|
(4.7
|
)
|
|
$
|
103.0
|
|
|
$
|
54.6
|
|
|
$
|
(106.4
|
)
|
|
$
|
46.5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures
|
(0.7
|
)
|
|
(5.3
|
)
|
|
(9.0
|
)
|
|
—
|
|
|
(15.0
|
)
|
|
(0.4
|
)
|
|
(3.6
|
)
|
|
(4.3
|
)
|
|
—
|
|
|
(8.3
|
)
|
Proceeds from sales of property, plant, and
equipment
|
—
|
|
|
0.1
|
|
|
13.2
|
|
|
—
|
|
|
13.3
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Acquisition of businesses, net of cash
acquired
|
(1,503.1
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1,503.1
|
)
|
|
—
|
|
|
—
|
|
|
(26.2
|
)
|
|
—
|
|
|
(26.2
|
)
|
Proceeds from divestiture, net of cash
divested
|
222.4
|
|
|
|
|
|
|
|
|
222.4
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Other, net
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.1
|
|
|
—
|
|
|
—
|
|
|
0.1
|
|
Net cash (used in) provided by investing
activities
|
(1,281.4
|
)
|
|
(5.2
|
)
|
|
4.2
|
|
|
—
|
|
|
(1,282.4
|
)
|
|
(0.4
|
)
|
|
(3.5
|
)
|
|
(30.5
|
)
|
|
—
|
|
|
(34.4
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of long-term debt
|
725.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
725.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Repayments on long-term debt
|
(9.1
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(9.1
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Proceeds from revolving credit facilities
|
804.0
|
|
|
—
|
|
|
278.8
|
|
|
—
|
|
|
1,082.8
|
|
|
164.0
|
|
|
—
|
|
|
178.0
|
|
|
—
|
|
|
342.0
|
|
Repayments on revolving credit facilities
|
(338.0
|
)
|
|
—
|
|
|
(206.7
|
)
|
|
—
|
|
|
(544.7
|
)
|
|
(130.8
|
)
|
|
—
|
|
|
(193.0
|
)
|
|
—
|
|
|
(323.8
|
)
|
Payment of deferred financing costs
|
(7.0
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(7.0
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Payment of dividends - intercompany
|
—
|
|
|
(96.1
|
)
|
|
(6.4
|
)
|
|
102.5
|
|
|
—
|
|
|
—
|
|
|
(100.0
|
)
|
|
(6.4
|
)
|
|
106.4
|
|
|
—
|
|
Payment of dividends on common stock
|
(31.7
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(31.7
|
)
|
|
(26.2
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(26.2
|
)
|
Proceeds from stock option exercises
|
0.2
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.2
|
|
|
1.4
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1.4
|
|
Payments for employee taxes on net
settlement equity awards
|
(1.8
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1.8
|
)
|
|
(4.2
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(4.2
|
)
|
Other, net
|
—
|
|
|
—
|
|
|
(1.1
|
)
|
|
—
|
|
|
(1.1
|
)
|
|
—
|
|
|
—
|
|
|
(0.5
|
)
|
|
—
|
|
|
(0.5
|
)
|
Net cash provided by (used in)
financing activities
|
1,141.6
|
|
|
(96.1
|
)
|
|
64.6
|
|
|
102.5
|
|
|
1,212.6
|
|
|
4.2
|
|
|
(100.0
|
)
|
|
(21.9
|
)
|
|
106.4
|
|
|
(11.3
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rates on cash and
cash equivalents
|
—
|
|
|
—
|
|
|
(0.5
|
)
|
|
—
|
|
|
(0.5
|
)
|
|
—
|
|
|
—
|
|
|
2.1
|
|
|
—
|
|
|
2.1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash flow
|
(137.8
|
)
|
|
1.9
|
|
|
110.9
|
|
|
—
|
|
|
(25.0
|
)
|
|
(0.9
|
)
|
|
(0.5
|
)
|
|
4.3
|
|
|
—
|
|
|
2.9
|
|
Cash, cash equivalents and restricted cash at
beginning of period
|
283.1
|
|
|
9.6
|
|
|
106.7
|
|
|
—
|
|
|
399.4
|
|
|
1.1
|
|
|
5.8
|
|
|
49.6
|
|
|
—
|
|
|
56.5
|
|
Cash, cash equivalents and restricted cash at
end of period
|
$
|
145.3
|
|
|
$
|
11.5
|
|
|
$
|
217.6
|
|
|
$
|
—
|
|
|
$
|
374.4
|
|
|
$
|
0.2
|
|
|
$
|
5.3
|
|
|
$
|
53.9
|
|
|
$
|
—
|
|
|
$
|
59.4
|
|
The following schedule details the restructuring charges by reportable segment and the classification of those charges in the Consolidated Statements of Operations.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2020
|
|
Three Months Ended March 31, 2019
|
|
Cost of goods sold
|
|
Operating expenses
|
|
Total
|
|
Cost of goods sold
|
|
Operating expenses
|
|
Total
|
Process Equipment Group
|
$
|
—
|
|
|
$
|
0.3
|
|
|
$
|
0.3
|
|
|
$
|
0.2
|
|
|
$
|
—
|
|
|
$
|
0.2
|
|
Milacron
|
(0.2
|
)
|
|
0.4
|
|
|
0.2
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Batesville
|
—
|
|
|
0.1
|
|
|
0.1
|
|
|
0.1
|
|
|
0.4
|
|
|
0.5
|
|
Corporate
|
—
|
|
|
0.7
|
|
|
0.7
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Total
|
$
|
(0.2
|
)
|
|
$
|
1.5
|
|
|
$
|
1.3
|
|
|
$
|
0.3
|
|
|
$
|
0.4
|
|
|
$
|
0.7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended March 31, 2020
|
|
Six Months Ended March 31, 2019
|
|
Cost of goods sold
|
|
Operating expenses
|
|
Total
|
|
Cost of goods sold
|
|
Operating expenses
|
|
Total
|
Process Equipment Group
|
$
|
0.7
|
|
|
$
|
1.2
|
|
|
$
|
1.9
|
|
|
$
|
0.4
|
|
|
$
|
0.1
|
|
|
$
|
0.5
|
|
Milacron
|
(0.2
|
)
|
|
1.2
|
|
|
1.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Batesville
|
0.1
|
|
|
0.4
|
|
|
0.5
|
|
|
0.2
|
|
|
0.5
|
|
|
0.7
|
|
Corporate
|
—
|
|
|
1.0
|
|
|
1.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Total
|
$
|
0.6
|
|
|
$
|
3.8
|
|
|
$
|
4.4
|
|
|
$
|
0.6
|
|
|
$
|
0.6
|
|
|
$
|
1.2
|
|
The restructuring charges during the three and six months ended March 31, 2020 and 2019 related primarily to severance costs. The severance costs within the Milacron and Corporate reportable segments were primarily related to the ongoing integration of Milacron. At March 31, 2020, $3.4 of restructuring costs were accrued and expected to be paid over the next twelve months.
20. Subsequent Events
The challenges posed by the COVID-19 pandemic on the global economy increased significantly as the quarter progressed and in the period after quarter end through the date of this filing, impacting the Company’s manufacturing capacity and customer demand in certain geographies. COVID-19 has spread across the globe during 2020 and is impacting economic activity worldwide. In response to COVID-19, national and local governments around the world have instituted certain measures, including travel restrictions, business curtailments, shelter-in-place orders, and social distancing guidelines. In addition to the impairment charges recorded during the three months ended March 31, 2020, the Company is continuing to evaluate the impact on its Consolidated Financial Statements and operational and financial performance that may result from the actions taken by the Company and its customers and suppliers in respect to this pandemic. The Company elected to draw an additional $75.0 on the Revolver on April 7, 2020 for general working capital requirements as a result of the COVID-19 pandemic.